ASX Code,Company Name,Item,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016
AAH,Arana Therapeutics Limited,Annual Ratio Analysis - ROE,-16.88%,-11.04%,2.80%,0.81%,0.82%,-99.27%,-29.07%,-14.20%,-17.06%,-8.54%,3.74%,56.23%,-17.33%,-46.24%,49.80%,33.68%,5.93%,1.07%,-1.51%, , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Profit and Loss - Operating Revenue,"514,000.00","912,000.00","2,242,000.00","3,061,000.00","3,045,000.00","4,118,000.00","3,684,000.00","889,000.00","1,982,000.00","2,285,000.00","3,219,000.00","28,190,000.00","3,702,000.00","2,094,000.00","44,373,000.00","5,882,000.00","5,817,000.00","8,126,000.00","7,519,000.00", , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-3,211,000.00","-1,846,000.00","1,066,000.00","2,045,000.00","1,613,000.00","-50,443,000.00","-5,307,000.00","-11,028,000.00","-25,077,000.00","-874,000.00","-314,000.00","30,667,000.00","-8,925,000.00","-15,771,000.00","28,341,000.00","25,711,000.00","5,093,000.00","133,414,000.00","-4,092,000.00", , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Balance Sheet - Total Equity,"26,278,000.00","27,942,000.00","45,697,000.00","79,077,000.00","90,167,000.00","74,199,000.00","55,630,000.00","45,680,000.00","11,337,000.00","10,232,000.00","9,898,000.00","46,226,000.00","39,962,000.00","34,107,000.00","66,023,000.00","76,332,000.00","85,945,000.00","309,246,000.00","304,073,000.00", , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Balance Sheet - Total Assets,"48,586,000.00","49,323,000.00","69,011,000.00","113,570,000.00","128,904,000.00","136,542,000.00","103,676,000.00","80,312,000.00","48,755,000.00","45,943,000.00","21,835,000.00","50,126,000.00","41,763,000.00","36,581,000.00","69,390,000.00","84,441,000.00","100,186,000.00","329,484,000.00","329,513,000.00", , , , , , , , 
ACL,Alchemia Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-24.87%,-29.43%,-63.17%,-33.35%,-45.97%,-33.65%,-34.05%,-27.91%,-71.38%,-62.16%,-14.73%,-25.60%,-13.70%, 
ACL,Alchemia Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,0.00,0.00,0.00,"26,000.00","768,000.00","9,000.00",0.00,0.00,0.00,"6,000.00","10,165,000.00","8,135,000.00","5,583,000.00", 
ACL,Alchemia Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-6,863,596.00","-6,522,000.00","-8,853,000.00","-12,732,000.00","-12,929,000.00","-10,943,000.00","-8,367,000.00","-8,801,000.00","-13,430,000.00","-15,083,000.00","-4,770,000.00","-6,924,000.00","-15,816,000.00", 
ACL,Alchemia Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"27,592,826.00","22,159,000.00","14,014,000.00","40,426,000.00","28,127,000.00","32,520,000.00","24,571,000.00","31,531,000.00","18,814,000.00","24,265,000.00","32,379,000.00","27,050,000.00","11,509,000.00", 
ACL,Alchemia Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"29,746,582.00","25,575,000.00","17,778,000.00","52,299,000.00","35,067,000.00","39,680,000.00","30,606,000.00","37,230,000.00","24,325,000.00","32,371,000.00","41,486,000.00","33,996,000.00","14,632,000.00", 
ACR,Acrux Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,-17.99%,-51.27%,-50.44%,-20.42%,-48.29%,-43.08%,-13.19%,-24.71%,57.85%,125.02%,13.92%,14.81%,66.50%,27.40%, 
ACR,Acrux Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,--,"746,307.00","3,264,806.00","3,471,736.00","1,481,000.00","4,044,000.00","4,496,000.00","1,323,000.00","55,069,000.00","89,603,000.00","8,797,000.00","15,585,000.00","53,368,000.00","24,616,000.00", 
ACR,Acrux Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,"-3,144,783.00","-5,956,800.00","-4,232,632.00","-6,044,034.00","-9,939,000.00","-7,861,000.00","-5,026,000.00","-7,716,000.00","46,554,000.00","57,148,000.00","7,391,000.00","6,926,000.00","27,970,000.00","11,130,000.00", 
ACR,Acrux Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,"17,485,116.00","11,664,921.00","8,408,905.00","29,481,791.00","20,583,000.00","18,246,000.00","38,109,000.00","31,223,000.00","80,469,000.00","45,712,000.00","53,103,000.00","46,753,000.00","42,057,000.00","40,625,000.00", 
ACR,Acrux Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,"18,355,576.00","12,846,083.00","9,757,512.00","31,093,624.00","23,234,000.00","20,369,000.00","41,267,000.00","34,950,000.00","83,605,000.00","58,995,000.00","58,499,000.00","52,895,000.00","53,221,000.00","48,495,000.00", 
ACW,Actinogen Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , ,-15.24%,-48.73%,-63.13%,-70.96%,-248.33%,-84.72%,-34.47%,-35.36%, 
ACW,Actinogen Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , ,"13,639.00","25,589.00","48,411.00","58,820.00","51,562.00",0.00,"20,000.00",0.00, 
ACW,Actinogen Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , ,"-435,658.00","-926,942.00","-737,471.00","-742,380.00","-1,529,156.00","-164,663.00","-440,222.00","-5,431,009.00", 
ACW,Actinogen Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , ,"2,859,172.00","1,902,230.00","1,168,259.00","1,046,127.00","346,990.00","194,353.00","1,211,812.00","15,356,608.00", 
ACW,Actinogen Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , ,"2,941,506.00","2,007,649.00","1,341,837.00","1,140,807.00","465,799.00","275,672.00","1,261,739.00","15,579,248.00", 
ADO,Anteo Diagnostics Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,0.03%,-7.47%,-13.74%,-54.97%,-62.88%,-116.88%,-255.93%,-392.34%,-100.88%,-58.54%,-188.77%,-161.75%,-32.25%,-49.87%,-78.51%,-35.09%,-78.93%, 
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,0.00,"55,640.00","1,291,151.00","3,989,863.00","4,280,284.00","1,991,478.00","809,604.00","91,141.00","81,114.00","226,312.00","265,752.00","210,063.00","405,175.00","510,294.00","309,759.00","465,131.00", 
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"2,039.00","-546,592.00","-1,401,000.00","-9,163,678.00","-2,946,256.00","-2,829,397.00","-1,579,539.00","-6,245,124.00","-1,563,497.00","-1,762,320.00","-1,949,275.00","-2,255,405.00","-2,222,462.00","-2,380,199.00","-2,179,223.00","-2,492,150.00","-4,220,342.00", 
ADO,Anteo Diagnostics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"7,854,309.00","7,314,683.00","10,199,317.00","6,372,825.00","3,455,730.00","2,107,897.00","526,706.00","1,591,757.00","1,549,861.00","3,010,212.00","1,032,600.00","1,394,366.00","6,891,174.00","4,772,565.00","2,775,766.00","7,101,335.00","5,346,863.00", 
ADO,Anteo Diagnostics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"7,865,442.00","7,932,728.00","11,527,497.00","7,971,025.00","5,037,306.00","3,434,580.00","732,065.00","1,908,617.00","1,958,564.00","3,472,095.00","1,332,129.00","1,723,206.00","7,285,267.00","5,211,398.00","3,275,348.00","7,666,936.00","6,043,268.00", 
AFP,AFT Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , , ,-47.00%
AFP,AFT Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , , ,"57,670,270.00"
AFP,AFT Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , , ,"-11,952,252.00"
AFP,AFT Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , , ,"25,432,432.00"
AFP,AFT Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , , ,"58,832,432.00"
AGX,Agenix Limited,Annual Ratio Analysis - ROE,-42.32%,-39.94%,-170.24%,-99.38%,0.45%,-19.74%,-98.40%,-23.81%,-14.77%,8.20%,2.96%,12.13%,4.73%,4.68%,-27.61%,-90.90%,-96.88%,-59.20%,-324.18%,"1,432.45%",87.06%,-136.24%,-130.56%,"-1,544.79%",-139.87%,-91.18%, 
AGX,Agenix Limited,Annual Profit and Loss - Operating Revenue,"81,000.00","387,000.00","629,000.00","480,000.00","706,000.00","745,000.00","3,504,715.00","4,395,733.00","4,718,933.00","18,230,788.00","26,158,907.00","29,254,351.00","37,490,000.00","33,604,000.00","31,952,000.00","22,179,000.00","560,000.00","342,000.00","247,000.00","717,000.00","37,666.00",--,0.00,"3,745.00","25,382.00",0.00, 
AGX,Agenix Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,940,000.00","-701,000.00","-869,000.00","-642,000.00","-290,000.00","-347,000.00","-1,849,053.00","-768,579.00","-4,421,147.00","1,074,289.00","4,923,828.00","4,200,596.00","161,000.00","-811,000.00","-14,336,000.00","-11,988,000.00","-3,721,000.00","-4,778,000.00","-23,283,000.00","-7,954,000.00","2,478,187.00","-2,707,451.00","-1,355,204.00","-3,258,469.00","786,160.00","-1,083,446.00", 
AGX,Agenix Limited,Annual Balance Sheet - Total Equity,"1,744,000.00","1,755,000.00","168,000.00","646,000.00","1,339,000.00","1,758,000.00","1,879,148.00","3,227,532.00","14,683,598.00","15,421,587.00","21,649,963.00","34,384,972.00","34,696,000.00","33,968,000.00","20,282,000.00","8,710,000.00","14,211,000.00","19,752,000.00","7,137,000.00","-490,000.00","2,846,399.00","1,987,201.00","1,038,009.00","210,933.00","1,387,079.00","848,719.00", 
AGX,Agenix Limited,Annual Balance Sheet - Total Assets,"2,452,000.00","2,753,000.00","7,729,000.00","7,324,000.00","7,932,000.00","2,153,000.00","4,681,471.00","4,163,720.00","34,113,819.00","33,534,906.00","33,122,832.00","44,038,165.00","45,613,000.00","45,781,000.00","35,616,000.00","24,589,000.00","23,654,000.00","33,803,000.00","13,579,000.00","2,649,000.00","5,802,446.00","2,836,753.00","1,207,316.00","725,379.00","2,092,299.00","1,694,819.00", 
ANP,Antisense Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-1.97%,-46.89%,-52.50%,-26.90%,-57.67%,-62.12%,-80.37%,-33.73%,-67.47%,-254.81%,-89.86%,-34.21%,-52.83%,-144.39%,9.97%, 
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,--,0.00,0.00,0.00,0.00,0.00,"-3,408.00","6,399,000.00",0.00,0.00,0.00,0.00,0.00,0.00,"3,863,988.00", 
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-393,739.00","-6,321,006.00","-6,107,898.00","-4,609,624.00","-6,265,839.00","-5,462,401.00","-4,835,963.00","-2,136,886.00","-2,649,727.00","-3,424,875.00","-1,813,550.00","-1,801,278.00","-2,454,842.00","-3,013,272.00","706,918.00", 
ANP,Antisense Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"20,033,762.00","13,481,712.00","11,617,746.00","17,132,983.00","10,864,344.00","8,793,236.00","6,017,376.00","6,334,646.00","3,927,502.00","1,344,099.00","2,018,122.00","5,265,844.00","4,647,055.00","2,086,891.00","7,091,598.00", 
ANP,Antisense Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"20,088,222.00","15,334,216.00","11,982,149.00","18,151,131.00","11,222,068.00","9,116,265.00","8,049,769.00","9,865,525.00","4,989,230.00","1,815,525.00","2,435,861.00","5,689,132.00","5,201,156.00","2,656,021.00","7,673,038.00", 
ANR,Anatara Lifesciences Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-32.75%, 
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,0.00, 
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-1,795,228.00", 
ANR,Anatara Lifesciences Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"7,226,054.00","5,480,816.00", 
ANR,Anatara Lifesciences Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"7,453,671.00","5,627,794.00", 
APH,Ascent Pharmahealth Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,-2.84%,-11.85%,-14.94%,7.00%,2.96%,8.79%,10.43%, , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,--,"1,795,000.00","54,575,000.00","40,383,000.00","106,854,000.00","137,757,000.00", , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-985,427.00","-3,672,693.00","-5,601,000.00","-17,961,000.00","1,532,000.00","9,177,000.00","11,962,000.00", , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"34,678,810.00","30,992,306.00","37,484,000.00","72,810,000.00","103,464,000.00","104,404,000.00","114,721,000.00", , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"34,830,053.00","31,253,547.00","40,782,000.00","102,659,000.00","139,116,000.00","142,071,000.00","157,252,000.00", , , , , , 
AVH,Avita Medical Ltd,Annual Ratio Analysis - ROE, , , ,-4.81%,-3.85%,-8.04%,-14.45%,-128.74%,-51.00%,-26.67%,-29.46%,-24.66%,-18.73%,-31.25%,-57.57%,-82.42%,-79.70%,-116.42%,-89.99%,-59.70%,-60.68%,-25.08%,-88.00%,-77.41%,-93.14%,-168.55%, 
AVH,Avita Medical Ltd,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"346,473.00","522,859.00","556,504.00","1,436,891.00","1,190,469.00","932,581.00","1,256,588.00","2,430,147.00","2,702,219.00","3,120,984.00","3,352,268.00","2,814,990.00","2,683,133.00","2,750,176.00", 
AVH,Avita Medical Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-333,000.00","-2,498,000.00","-1,727,000.00","231,652.00","-3,519,806.00","-923,381.00","-1,241,305.00","-2,932,839.00","-2,529,112.00","-2,688,501.00","-1,983,430.00","-7,129,289.00","-14,156,687.00","-11,973,869.00","-15,065,061.00","-12,188,280.00","-5,128,292.00","-5,889,363.00","-1,796,920.00","-7,671,682.00","-8,092,939.00","-5,147,391.00","-7,107,496.00", 
AVH,Avita Medical Ltd,Annual Balance Sheet - Total Equity, , , ,"9,667,000.00","7,499,000.00","6,022,000.00","6,253,774.00","2,733,968.00","1,810,587.00","4,654,569.00","9,661,767.00","8,882,655.00","14,703,496.00","12,692,981.00","12,383,365.00","17,176,702.00","15,023,589.00","12,940,765.00","13,543,855.00","8,589,881.00","4,678,054.00","16,050,495.00","8,553,977.00","10,455,310.00","5,526,622.00","4,216,884.00", 
AVH,Avita Medical Ltd,Annual Balance Sheet - Total Assets, , , ,"10,231,000.00","7,810,000.00","6,137,000.00","6,316,252.00","2,763,173.00","1,843,096.00","4,788,612.00","9,727,236.00","9,909,377.00","15,262,355.00","13,425,192.00","13,114,639.00","19,002,091.00","17,623,673.00","14,198,988.00","16,206,113.00","9,829,464.00","9,243,405.00","17,486,837.00","10,706,070.00","12,908,631.00","7,312,839.00","5,443,166.00", 
AVT,AVT Plasma Limited,Annual Ratio Analysis - ROE, , , , ,24.13%,17.45%,-29.74%,-60.84%,-160.63%,-20.01%,-27.79%,-248.03%,-368.15%,-273.38%,677.40%, , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Profit and Loss - Operating Revenue, , , , ,"15,564,000.00","20,889,000.00","13,643,053.00","15,751,760.00","2,728,028.00",--,--,--,--,--,"7,190.00", , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,"4,431,000.00","4,267,000.00","-9,193,383.00","-15,283,893.00","7,034,930.00","-1,406,856.00","-2,352,000.00","-7,980,126.00","-986,715.00","-4,679,268.00","-2,151,344.00", , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Balance Sheet - Total Equity, , , , ,"18,318,000.00","22,686,000.00","12,057,996.00","-2,179,205.00","4,711,504.00","7,032,452.00","8,464,860.00","1,254,734.00","268,019.00","1,711,654.00","-317,590.00", , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Balance Sheet - Total Assets, , , , ,"33,387,000.00","42,272,000.00","42,227,477.00","42,318,329.00","4,764,125.00","7,387,158.00","8,674,337.00","1,972,332.00","383,264.00","2,429,654.00","232,292.00", , , , , , , , , , , , 
AVX,Avexa Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-64.12%,-105.38%,-16.67%,-64.71%,-84.66%,-64.53%,-16.70%,-20.63%,-21.99%,-25.25%,-25.26%, 
AVX,Avexa Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"669,000.00",--,0.00,"891,000.00",0.00,"398,000.00",0.00,0.00,0.00,"295,000.00",0.00, 
AVX,Avexa Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-13,536,000.00","-17,830,000.00","-15,218,000.00","-36,093,000.00","-36,218,000.00","-41,488,000.00","-4,402,000.00","-3,513,000.00","-2,977,000.00","-2,897,000.00","-6,610,000.00", 
AVX,Avexa Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"21,112,000.00","16,920,000.00","91,290,000.00","55,776,000.00","42,783,000.00","24,369,000.00","26,355,000.00","17,029,000.00","13,539,000.00","11,471,000.00","6,374,000.00", 
AVX,Avexa Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"21,993,000.00","20,585,000.00","93,978,000.00","64,783,000.00","45,777,000.00","25,478,000.00","26,828,000.00","17,620,000.00","14,013,000.00","11,923,000.00","6,651,000.00", 
BDM,BioDiem Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,9.83%,-33.24%,-56.67%,-106.10%,-143.56%,-82.40%,-37.96%,-81.60%,-104.81%,-67.26%,-216.98%, , , 
BDM,BioDiem Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"5,262,198.00",--,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00, , , 
BDM,BioDiem Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"1,422,481.00","-3,233,256.00","-4,264,383.00","-2,847,618.00","-3,851,867.00","-4,470,506.00","-1,513,742.00","-3,391,630.00","-2,618,933.00","-1,009,384.00","-2,316,160.00", , , 
BDM,BioDiem Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"14,478,118.00","9,726,075.00","5,461,692.00","2,683,887.00","2,683,051.00","5,425,190.00","3,987,394.00","4,156,418.00","2,498,730.00","1,500,768.00","1,067,446.00", , , 
BDM,BioDiem Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"14,682,487.00","9,903,583.00","5,832,168.00","2,921,022.00","2,997,451.00","5,676,976.00","4,061,829.00","4,320,521.00","2,683,211.00","1,760,628.00","1,355,551.00", , , 
BGN,BresaGen Limited,Annual Ratio Analysis - ROE, , , , , , ,--,--,-13.45%,-212.54%,-15.83%,-14.96%,-37.22%,-54.43%,-146.04%,-351.11%,-7.70%, , , , , , , , , , 
BGN,BresaGen Limited,Annual Profit and Loss - Operating Revenue, , , , , , ,"3,493,000.00","3,225,000.00","3,227,000.00","613,838.00","909,000.00","3,172,000.00","2,220,000.00","2,626,000.00","2,386,000.00","1,887,000.00","5,563,000.00", , , , , , , , , , 
BGN,BresaGen Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"-1,383,000.00","-1,816,000.00","-2,492,000.00","-2,194,939.00","-3,342,000.00","-6,469,000.00","-11,861,000.00","-13,946,000.00","-10,658,000.00","-8,093,000.00","-291,000.00", , , , , , , , , , 
BGN,BresaGen Limited,Annual Balance Sheet - Total Equity, , , , , , ,--,--,"18,523,000.00","1,032,729.00","21,116,000.00","43,231,000.00","31,866,000.00","17,956,000.00","7,298,000.00","2,305,000.00","3,779,000.00", , , , , , , , , , 
BGN,BresaGen Limited,Annual Balance Sheet - Total Assets, , , , , , ,--,--,"13,282,000.00","6,478,652.00","22,532,000.00","44,732,000.00","34,472,000.00","27,791,000.00","17,928,000.00","12,285,000.00","12,095,000.00", , , , , , , , , , 
BIT,Biotron Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-12.69%,-19.65%,-47.36%,-94.90%,-82.66%,-48.91%,-238.49%,-102.10%,-211.06%,-109.01%,-79.47%,-28.76%,-86.05%,-222.11%,-65.73%, 
BIT,Biotron Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,"13,060.00","62,740.00",--,0.00,0.00,"794,862.00","402,457.00",0.00,0.00,--,0.00,0.00,0.00,0.00,0.00, 
BIT,Biotron Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00,"-1,279,663.00","-1,667,894.00","-2,728,701.00","-2,805,115.00","-1,883,575.00","-2,198,973.00","-3,234,004.00","-1,882,093.00","-1,776,099.00","-1,872,244.00","-1,907,527.00","-2,378,052.00","-3,850,745.00","-3,085,814.00","-2,723,221.00", 
BIT,Biotron Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"42,221,000.00","10,080,657.00","8,489,713.00","5,761,012.00","2,955,897.00","2,278,730.00","4,495,848.00","1,356,015.00","1,843,377.00","841,506.00","1,717,558.00","2,400,300.00","8,269,547.00","4,475,110.00","1,389,296.00","4,143,026.00", 
BIT,Biotron Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"42,221,000.00","10,192,106.00","8,632,608.00","5,909,088.00","3,109,230.00","2,428,608.00","4,813,956.00","1,519,038.00","2,267,322.00","1,063,838.00","1,857,845.00","2,644,620.00","8,461,726.00","4,866,189.00","1,863,940.00","4,616,202.00", 
BLT,Benitec Biopharma Limited,Annual Ratio Analysis - ROE, , , , , , , ,-33.53%,-50.83%,-65.01%,-241.12%,-154.89%,-7.43%,-116.87%,-32.31%,-58.53%,-789.36%,-55.12%,-204.32%,-215.07%,378.34%,-55.22%,-154.44%,-309.94%,-20.99%,-48.20%, 
BLT,Benitec Biopharma Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,--,"115,673.00","602,391.00","681,136.00","239,968.00","333,938.00","673,029.00","91,559.00","923,200.00","3,690,112.00","402,589.00",0.00,0.00,0.00,0.00,0.00,0.00,"276,824.00","307,000.00", 
BLT,Benitec Biopharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-793,760.00","-848,469.00","-2,105,226.00","-1,110,000.00","-1,539,561.00","-1,124,036.00","-8,229,667.00","-7,827,227.00","-14,562,565.00","-7,676,840.00","-2,746,753.00","-2,774,690.00","-2,470,671.00","-4,640,671.00","-3,534,874.00","-4,112,617.00","-3,487,960.00","-7,039,109.00","-11,509,000.00", 
BLT,Benitec Biopharma Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"2,367,661.00","1,669,192.00","1,574,211.00","460,361.00","993,995.00","15,132,693.00","6,903,026.00","24,226,535.00","24,879,189.00","62,637.00","3,643,393.00","1,358,035.00","1,148,784.00","-696,674.00","5,204,348.00","2,662,914.00","640,340.00","33,540,522.00","23,878,000.00", 
BLT,Benitec Biopharma Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"2,538,195.00","1,792,822.00","2,379,621.00","2,456,012.00","2,380,398.00","17,227,965.00","14,325,483.00","26,942,104.00","28,455,577.00","2,285,384.00","5,216,052.00","2,020,228.00","1,997,948.00","1,037,162.00","6,865,358.00","3,251,206.00","1,750,710.00","34,495,202.00","25,520,000.00", 
BNC,Bioniche Life Sciences Inc,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , ,0.00%,-70.06%,-153.59%,269.42%, , , 
BNC,Bioniche Life Sciences Inc,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , ,--,"26,341,322.00","28,516,357.00","84,544.00", , , 
BNC,Bioniche Life Sciences Inc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , ,0.00,"-14,761,767.00","-23,137,555.00","-31,387,771.00", , , 
BNC,Bioniche Life Sciences Inc,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , ,"39,991,087.00","21,071,325.00","15,064,090.00","-12,931,230.00", , , 
BNC,Bioniche Life Sciences Inc,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , ,"88,612,967.00","67,029,550.00","78,584,273.00","63,411,691.00", , , 
BNO,Bionomics Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,61.83%,-28.03%,-32.19%,-43.05%,-67.62%,-40.02%,-43.38%,-49.30%,-24.01%,-22.22%,-36.71%,-32.26%,-32.60%,-12.11%,-24.15%,7.15%,-54.71%, 
BNO,Bionomics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,0.00,--,0.00,"1,611,599.00","1,028,243.00",0.00,"295,552.00","652,375.00","817,295.00","1,125,995.00","3,610,495.00","2,993,308.00","3,183,179.00","1,126,113.00","1,637,207.00","19,142,065.00","6,629,113.00", 
BNO,Bionomics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-337,000.00","-1,418,874.00","-3,279,252.00","-3,489,730.00","-4,540,955.00","-3,574,582.00","-4,632,314.00","-5,396,950.00","-5,449,798.00","-4,783,917.00","-6,862,299.00","-8,214,082.00","-9,356,497.00","-3,136,238.00","-10,001,350.00","3,206,616.00","-16,949,405.00", 
BNO,Bionomics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"-545,000.00","5,062,021.00","10,186,951.00","9,988,858.00","6,715,090.00","8,930,891.00","10,679,038.00","10,946,278.00","22,698,596.00","21,527,425.00","18,694,568.00","25,465,888.00","28,699,180.00","25,899,117.00","41,406,983.00","44,818,607.00","31,965,825.00", 
BNO,Bionomics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"213,000.00","5,307,946.00","10,829,271.00","15,838,595.00","12,570,687.00","14,961,612.00","17,049,593.00","19,714,759.00","30,820,997.00","28,313,400.00","24,724,686.00","31,514,471.00","34,308,899.00","31,102,188.00","53,611,092.00","65,060,617.00","69,131,715.00", 
BOT,Botanix Pharmaceuticals Ltd,Annual Ratio Analysis - ROE,0.51%,10.06%,10.28%,7.58%,19.03%,15.88%,11.20%,-25.78%,-37.54%,-94.83%,-30.10%,-6.20%,-31.04%,-52.80%,-26.53%,-84.27%,-125.11%,-117.96%,-219.68%,-346.74%,219.59%,68.11%,67.19%,73.96%,-50.41%,-42.92%, 
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - Operating Revenue,"21,000,000.00","25,515,000.00","26,824,000.00","33,084,000.00","45,027,000.00","66,645,000.00","41,329,000.00","35,061,000.00","34,895,000.00","25,377,000.00","9,143,000.00",0.00,"369,379.00","925,374.00","457,505.00",0.00,0.00,--,--,--,--,--,--,--,0.00,--, 
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"-210,000.00","961,000.00","-1,766,000.00","1,875,000.00","5,155,000.00","6,125,000.00","4,244,000.00","-12,806,000.00","-17,155,000.00","-7,581,000.00","-3,172,000.00","-353,018.00","-1,409,920.00","-1,398,571.00","-958,586.00","-29,766,350.00","-2,782,476.00","-3,416,963.00","-2,825,253.00","-3,043,463.00","-3,945,207.00","-1,519,744.00","-1,568,030.00","-1,849,884.00","-1,131,036.00","-1,014,541.00", 
BOT,Botanix Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity,"11,961,000.00","12,875,000.00","11,406,000.00","18,346,000.00","26,044,000.00","38,440,000.00","37,913,000.00","32,046,000.00","15,752,000.00","8,084,000.00","5,150,000.00","5,694,532.00","4,047,275.00","2,648,704.00","2,244,515.00","3,456,604.00","2,223,949.00","2,896,755.00","1,286,083.00","877,740.00","-1,796,608.00","-2,231,289.00","-2,333,643.00","-2,501,176.00","2,243,523.00","1,228,982.00", 
BOT,Botanix Pharmaceuticals Ltd,Annual Balance Sheet - Total Assets,"25,584,000.00","27,413,000.00","25,921,000.00","38,030,000.00","48,565,000.00","68,158,000.00","57,046,000.00","50,262,000.00","30,362,000.00","16,149,000.00","5,268,000.00","5,863,868.00","4,505,153.00","2,937,994.00","2,426,130.00","3,679,849.00","2,507,843.00","3,500,229.00","2,367,918.00","2,016,714.00","58,595.00","42,549.00","17,857.00","8,158.00","2,553,369.00","1,320,565.00", 
BPH,BPH Energy Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-24.81%,-22.35%,-33.85%,-35.23%,-225.56%,-7.45%,-0.43%,-1.51%,-1.18%,-1.10%,7.06%, 
BPH,BPH Energy Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,"10,000.00","436,183.00",0.00,"134,335.00","164,645.00","138,525.00",0.00,0.00,0.00,--, 
BPH,BPH Energy Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-727,639.00","-986,613.00","-1,339,391.00","-1,178,893.00","-2,240,611.00","-234,457.00","-267,884.00","-764,478.00","-594,908.00","-1,266,079.00","-26,490,513.00", 
BPH,BPH Energy Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"2,932,527.00","4,413,773.00","3,802,187.00","3,338,480.00","716,488.00","15,697,202.00","50,893,918.00","48,789,149.00","48,197,297.00","46,947,298.00","20,739,418.00", 
BPH,BPH Energy Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"2,960,739.00","5,032,042.00","4,634,886.00","4,058,522.00","1,515,626.00","16,637,216.00","56,329,812.00","54,192,811.00","53,328,510.00","52,018,922.00","22,485,897.00", 
BTA,Biota Holdings Limited,Annual Ratio Analysis - ROE,-13.21%,-5.07%,2.03%,-1.86%,3.60%,-8.84%,-9.49%,-16.34%,-15.95%,-16.35%,6.25%,-1.64%,-27.03%,-42.12%,-33.93%,-55.95%,-24.11%,28.21%,-10.25%,18.74%,11.78%,-39.76%,-32.24%, , , , 
BTA,Biota Holdings Limited,Annual Profit and Loss - Operating Revenue,0.00,"276,000.00","1,465,000.00","328,000.00","2,528,000.00","194,000.00","57,000.00",0.00,"24,000.00","303,000.00","1,728,000.00",0.00,"8,464,000.00","3,449,000.00","5,286,000.00","1,811,000.00","6,420,000.00","13,534,000.00","15,549,000.00","25,239,000.00","1,362,000.00","627,000.00","10,699,000.00", , , , 
BTA,Biota Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-304,000.00","-111,000.00","-1,679,000.00","-279,000.00","-31,827,000.00","-1,643,000.00","-2,155,000.00","-4,101,000.00","-6,460,000.00","-5,966,000.00","2,519,000.00","-718,000.00","-9,338,000.00","-11,002,000.00","-8,112,000.00","-14,831,000.00","-11,306,000.00","20,180,000.00","-6,489,000.00","38,181,000.00","16,235,000.00","-28,090,000.00","-18,814,000.00", , , , 
BTA,Biota Holdings Limited,Annual Balance Sheet - Total Equity,"2,301,000.00","2,190,000.00","5,892,000.00","10,760,000.00","9,487,000.00","18,040,000.00","22,707,000.00","25,099,000.00","40,507,000.00","36,484,000.00","40,275,000.00","40,288,000.00","30,950,000.00","21,588,000.00","21,620,000.00","26,036,000.00","46,898,000.00","71,535,000.00","63,300,000.00","97,032,000.00","104,896,000.00","76,856,000.00","58,353,000.00", , , , 
BTA,Biota Holdings Limited,Annual Balance Sheet - Total Assets,"2,768,000.00","2,626,000.00","7,079,000.00","11,083,000.00","21,905,000.00","18,669,000.00","23,276,000.00","25,557,000.00","41,214,000.00","37,469,000.00","43,761,000.00","41,441,000.00","35,097,000.00","25,226,000.00","26,175,000.00","30,427,000.00","57,559,000.00","92,454,000.00","89,258,000.00","111,629,000.00","122,167,000.00","83,561,000.00","68,084,000.00", , , , 
BXN,Bioxyne Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,-11.47%,-34.45%,-112.83%,-527.39%,-341.97%,"-2,103.51%",-457.39%,-806.40%,213.63%,-488.83%,65.00%,0.85%,-4.64%,"2,937.95%",24.37%,15.66%, 
BXN,Bioxyne Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,--,"261,472.00","1,408,449.00","1,090,995.00","1,388,812.00","1,684,644.00","785,996.00","674,563.00","1,103,288.00","751,897.00","984,982.00","123,275.00","880,497.00","2,305,227.00","1,492,109.00", 
BXN,Bioxyne Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"-1,426,259.00","-3,109,026.00","-4,803,987.00","-5,103,987.00","-4,337,044.00","-3,933,058.00","-1,877,981.00","-1,763,157.00","-1,331,146.00","-210,906.00","80,144.00","1,054.00","-1,784,131.00","-6,191,113.00","1,190,827.00","201,039.00", 
BXN,Bioxyne Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"12,431,420.00","9,024,579.00","4,257,592.00","967,783.00","1,175,273.00","186,976.00","410,583.00","218,646.00","-623,122.00","43,145.00","123,289.00","124,343.00","5,887,883.00","-210,729.00","1,071,915.00","1,283,666.00", 
BXN,Bioxyne Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"12,542,934.00","9,563,655.00","4,897,525.00","1,980,479.00","2,378,749.00","1,301,182.00","1,073,320.00","610,132.00","482,420.00","485,629.00","298,583.00","220,733.00","6,910,089.00","702,220.00","1,499,172.00","1,513,037.00", 
CDY,Cellmid Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,-50.06%,-297.12%,-436.76%,-451.44%,-47.03%,-111.37%,-93.63%,-28.65%,-26.02%,-88.43%, 
CDY,Cellmid Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,0.00,0.00,0.00,0.00,0.00,"31,418.00","141,199.00","542,055.00","2,196,613.00","1,842,804.00", 
CDY,Cellmid Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,"-2,760,092.00","-4,554,782.00","-2,688,804.00","-3,334,546.00","-1,339,948.00","-2,269,637.00","-1,972,483.00","-1,541,307.00","-1,480,836.00","-3,337,348.00", 
CDY,Cellmid Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"5,513,521.00","1,532,962.00","615,630.00","738,649.00","2,848,939.00","2,037,968.00","2,089,484.00","5,305,157.00","5,663,726.00","3,773,909.00", 
CDY,Cellmid Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"6,114,679.00","4,715,095.00","2,601,433.00","1,222,453.00","3,218,251.00","2,821,872.00","2,518,262.00","5,993,719.00","6,454,425.00","6,147,547.00", 
CMQ,Chemeq Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,-5.35%,-89.55%,-24.09%,-33.46%,-43.09%,-33.80%,-15.56%,-193.47%,"-2,316.68%", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,--,"1,159.00",0.00,--,"2,069.00",0.00,30.00,--,"154,000.00","1,785,000.00", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-245,394.00","-191,716.00","-420,953.00","-1,350,757.00","-1,432,502.00","-3,540,337.00","-7,272,893.00","-9,954,809.00","-60,670,000.00","-31,808,000.00", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,"3,585,909.00","470,086.00","5,607,207.00","4,280,708.00","8,215,997.00","21,447,998.00","63,979,138.00","31,359,000.00","1,373,000.00", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,"3,348,968.00","515,325.00","5,849,334.00","4,689,400.00","8,872,404.00","28,571,177.00","75,824,147.00","74,388,000.00","65,298,000.00", , , , , , , , , , 
CSL,CSL Limited,Annual Ratio Analysis - ROE, , , ,8.81%,6.73%,7.41%,8.49%,9.68%,10.48%,11.42%,6.86%,8.93%,9.72%,5.49%,3.69%,14.31%,17.63%,22.98%,25.01%,18.67%,24.98%,25.81%,28.66%,40.45%,41.33%,49.40%, 
CSL,CSL Limited,Annual Profit and Loss - Operating Revenue, , , ,"167,696,000.00","192,996,000.00","250,430,000.00","281,102,016.00","305,003,008.00","353,491,008.00","413,471,008.00","450,598,000.00","843,308,000.00","1,336,412,000.00","1,303,034,000.00","1,654,349,000.00","2,755,792,000.00","2,848,908,000.00","3,172,397,000.00","3,556,662,000.00","4,640,278,000.00","4,473,926,000.00","4,196,456,000.00","4,444,300,000.00","5,357,520,215.00","5,663,269,639.00","7,107,552,083.00", 
CSL,CSL Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"13,841,000.00","18,046,000.00","24,542,000.00","28,995,000.00","35,152,000.00","44,854,000.00","47,382,000.00","54,402,000.00","78,241,000.00","123,808,000.00","70,423,000.00","219,625,000.00","546,518,000.00","117,357,000.00","539,299,000.00","701,802,000.00","1,145,932,000.00","1,052,901,000.00","940,601,000.00","982,600,000.00","1,311,374,663.00","1,387,473,460.00","1,795,572,916.00", 
CSL,CSL Limited,Annual Balance Sheet - Total Equity, , , ,"156,827,000.00","316,576,000.00","331,248,000.00","341,556,000.00","363,044,000.00","390,262,000.00","414,921,992.00","793,580,000.00","875,958,000.00","1,273,131,000.00","1,282,698,000.00","2,074,042,000.00","2,074,512,000.00","1,989,804,000.00","2,268,849,000.00","2,806,125,000.00","5,462,895,000.00","4,215,194,000.00","3,644,360,000.00","3,428,300,000.00","3,241,832,884.00","3,356,687,898.00","3,576,692,708.00", 
CSL,CSL Limited,Annual Balance Sheet - Total Assets, , , ,"229,155,000.00","427,907,000.00","472,339,000.00","474,685,992.00","511,117,992.00","523,762,000.00","561,538,000.00","946,479,000.00","1,771,810,000.00","2,312,122,000.00","2,219,538,000.00","3,875,383,000.00","3,874,296,000.00","4,186,085,000.00","4,199,694,000.00","4,694,964,000.00","7,366,815,000.00","5,711,044,000.00","5,067,997,000.00","5,819,300,000.00","6,442,587,601.00","6,664,225,053.00","8,334,635,416.00", 
CST,Cellestis Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-5.80%,-19.40%,-27.72%,-44.04%,-17.25%,-24.63%,-17.41%,14.61%,37.03%,30.22%, , , , , , 
CST,Cellestis Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,"26,408.00","203,380.00","449,076.00","971,603.00","1,897,665.00","5,279,000.00","10,654,000.00","18,829,000.00","34,461,000.00","40,383,000.00", , , , , , 
CST,Cellestis Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,-8.00,"-293,000.00","-1,640,539.00","-2,374,941.00","-2,648,992.00","-3,068,638.00","-3,622,000.00","-2,277,000.00","2,256,000.00","8,232,000.00","8,253,000.00", , , , , , 
CST,Cellestis Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"10,431,992.00","10,102,927.00","8,456,493.00","8,566,686.00","6,014,992.00","17,793,471.00","14,705,000.00","13,082,000.00","15,443,000.00","22,231,000.00","27,312,000.00", , , , , , 
CST,Cellestis Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"10,454,409.00","10,279,445.00","8,655,833.00","8,973,968.00","6,473,232.00","19,114,692.00","16,749,000.00","15,852,000.00","19,592,000.00","29,589,000.00","35,656,000.00", , , , , , 
CTE,Cryosite Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-25.46%,-36.23%,-42.24%,-31.26%,-25.03%,3.60%,24.70%,10.35%,0.17%,0.11%,7.13%,18.66%,19.95%,8.24%,12.84%, 
CTE,Cryosite Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"2,427.00","460,919.00","1,902,666.00","2,092,836.00","2,955,056.00","4,097,100.00","4,722,572.00","6,467,582.00","6,158,392.00","5,968,601.00","6,432,973.00","7,757,568.00","8,497,803.00","9,171,014.00","9,594,375.00", 
CTE,Cryosite Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-984,991.00","-1,224,325.00","-1,170,000.00","-950,038.00","-620,311.00","101,374.00","922,744.00","447,059.00","7,249.00","4,612.00","334,305.00","1,022,479.00","1,249,961.00","505,602.00","455,170.00", 
CTE,Cryosite Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"3,868,363.00","3,889,894.00","2,769,834.00","3,038,890.00","2,477,872.00","2,813,290.00","3,735,965.00","4,321,088.00","4,340,310.00","4,354,687.00","4,691,383.00","5,480,664.00","6,264,228.00","6,135,137.00","3,544,435.00", 
CTE,Cryosite Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"4,048,063.00","4,358,889.00","3,524,617.00","4,402,858.00","4,661,088.00","5,113,844.00","6,397,666.00","7,248,518.00","7,354,556.00","7,682,293.00","8,625,134.00","9,770,324.00","11,362,227.00","11,633,480.00","9,122,755.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,-2.44%,-11.58%,-30.47%,-52.81%,-85.72%,-147.96%,-76.98%,-14.03%,-28.29%,-41.49%,-43.60%,-75.72%,-72.83%,-50.72%,-35.82%,-92.94%, 
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,--,--,--,--,"124,622.00","754,846.00","283,308.00",--,0.00,0.00,"1,041,021.00","722,801.00","1,552,998.00","2,200,092.00","2,911,553.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"-374,150.00","-1,557,582.00","-3,141,224.00","-3,976,770.00","-7,589,730.00","-11,029,031.00","-10,768,981.00","-9,176,123.00","-14,655,791.00","-15,372,907.00","-11,521,040.00","-11,409,089.00","-9,767,228.00","-6,802,823.00","-5,525,889.00","-10,414,376.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"15,317,497.00","13,450,758.00","10,309,534.00","7,530,715.00","8,854,501.00","7,454,262.00","13,988,832.00","65,391,816.00","51,814,516.00","37,051,184.00","26,426,163.00","16,408,101.00","13,637,336.00","13,839,290.00","15,427,732.00","11,205,291.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"15,441,036.00","13,769,023.00","10,520,362.00","8,066,166.00","10,246,943.00","10,055,643.00","17,070,859.00","67,824,745.00","54,970,758.00","41,613,762.00","29,506,783.00","20,165,457.00","15,995,277.00","15,814,791.00","17,153,568.00","13,643,875.00", 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Ratio Analysis - ROE,-54.43%,4.25%,80.86%,21.59%,-16.27%,-6.26%,-5.23%,-5.29%,-11.38%,-38.46%,-32.39%,-65.63%,"1,918.39%",-48.85%,-34.85%,-19.24%,-33.45%,-29.35%,-70.85%,-35.18%,-33.98%, , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,"781,000.00",0.00,0.00,0.00,0.00,"1,436,750.00","2,054,210.00","3,898,401.00","4,402,634.00","4,997,247.00","3,490,459.00","3,631,397.00","1,676,297.00","1,266,210.00",0.00,"990,132.00","17,806,000.00", , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"-5,237,000.00","-4,753,000.00","10,880,000.00","-1,845,000.00","8,030,000.00","3,770,000.00","8,827,739.00","-258,091.00","-5,828,000.00","-12,775,806.00","-9,034,000.00","-3,417,971.00","-7,465,913.00","-1,887,154.00","-5,139,077.00","-4,693,269.00","-10,369,719.00","-11,700,919.00","-6,419,926.00","-25,943,758.00","-6,018,000.00", , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity,"-7,621,000.00","-12,374,000.00","-1,494,000.00","-3,339,000.00","4,691,000.00","8,461,000.00","17,289,153.00","24,115,857.00","18,288,000.00","5,513,130.00","13,499,733.00","6,925,209.00","-389,175.00","3,862,864.00","14,745,081.00","24,387,320.00","31,004,909.00","39,869,598.00","24,509,366.00","73,751,454.00","69,206,000.00", , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Balance Sheet - Total Assets,"5,778,000.00","842,000.00","3,466,000.00","2,418,000.00","7,806,000.00","12,203,000.00","21,700,293.00","24,333,604.00","18,689,000.00","7,645,356.00","14,320,931.00","8,304,397.00","4,338,539.00","4,310,132.00","16,866,401.00","25,727,496.00","32,965,251.00","42,761,109.00","27,944,777.00","77,044,777.00","71,948,000.00", , , , , , 
CYP,Cynata Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-92.05%,-150.76%,-227.05%,-263.91%,-180.65%,-55.74%,-30.85%,-42.42%, 
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"350,565.00",0.00,"113,879.00","222,936.00","162,452.00","33,964.00",0.00,0.00, 
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-2,034,852.00","-1,450,271.00","-2,116,125.00","-2,564,979.00","-1,542,307.00","-915,701.00","-3,039,663.00","-3,712,077.00", 
CYP,Cynata Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"3,409,742.00","2,210,670.00","961,980.00","932,005.00","971,930.00","853,753.00","1,642,843.00","9,854,632.00","8,749,959.00", 
CYP,Cynata Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"3,556,905.00","2,327,549.00","1,420,237.00","1,248,816.00","1,217,855.00","1,016,839.00","1,792,543.00","9,925,928.00","9,125,352.00", 
CYT,Cytopia Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-10.97%,-15.22%,-18.47%,-30.16%,-38.07%,-31.87%,-22.93%,-22.38%,-35.47%,-67.13%,-130.20%, , , , , , , 
CYT,Cytopia Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,0.00,"18,204.00",0.00,0.00,0.00,"3,748,346.00",0.00,"4,404,517.00",0.00,0.00, , , , , , , 
CYT,Cytopia Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-769,054.00","-2,138,000.00","-3,167,317.00","-3,872,900.00","-4,846,590.00","-4,583,218.00","-5,118,905.00","-4,412,360.00","-4,947,260.00","-7,603,000.00","-6,515,767.00", , , , , , , 
CYT,Cytopia Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"8,085,540.00","12,489,285.00","16,534,642.00","12,745,818.00","11,544,778.00","13,530,312.00","22,322,898.00","19,719,112.00","13,949,164.00","11,325,000.00","5,004,376.00", , , , , , , 
CYT,Cytopia Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"8,676,171.00","12,575,290.00","16,977,310.00","13,315,111.00","12,272,063.00","14,253,119.00","23,039,964.00","26,021,001.00","17,967,899.00","14,566,000.00","6,342,020.00", , , , , , , 
DVL,Dorsavi Ltd,Annual Ratio Analysis - ROE, , , , , ,0.01%,4.02%,5.27%,0.98%, , , , , , , , , , , , , , ,0.00%,-24.36%,-121.45%, 
DVL,Dorsavi Ltd,Annual Profit and Loss - Operating Revenue, , , , , ,0.00,0.00,0.00,0.00, , , , , , , , , , , , , , ,--,"529,000.00","1,476,973.00", 
DVL,Dorsavi Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"2,000.00","725,461.00","1,104,788.00","228,143.00", , , , , , , , , , , , , , ,0.00,"-3,562,000.00","-8,036,161.00", 
DVL,Dorsavi Ltd,Annual Balance Sheet - Total Equity, , , , , ,"14,927,000.00","18,048,988.00","20,956,228.00","23,380,694.00", , , , , , , , , , , , , , ,"18,492,815.00","14,620,000.00","6,616,716.00", 
DVL,Dorsavi Ltd,Annual Balance Sheet - Total Assets, , , , , ,"14,949,000.00","18,107,147.00","21,026,242.00","23,599,618.00", , , , , , , , , , , , , , ,"18,875,881.00","15,339,000.00","8,017,330.00", 
DXB,Dimerix Limited,Annual Ratio Analysis - ROE,-3.41%,1.63%,-0.10%,-3.12%,-7.58%,-7.13%,-6.68%,-7.18%,11.90%,11.20%,-5.58%,-401.98%,-261.47%,176.44%,396.85%,-11.51%,-112.18%,-171.17%,-352.86%,-140.10%,-22.29%,0.36%,-32.72%,-30.29%,-44.78%,-20.87%, 
DXB,Dimerix Limited,Annual Profit and Loss - Operating Revenue,"114,000.00","9,000.00",0.00,0.00,0.00,0.00,0.00,0.00,"4,017,426.00","10,731,454.00","8,090,419.00","5,343,004.00","4,090,520.00","2,487,216.00","2,704,726.00","1,369,138.00",564.00,"655,993.00","756,957.00",--,0.00,"73,068.00",0.00,0.00,0.00,0.00, 
DXB,Dimerix Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-119,000.00","-344,000.00","-1,000.00","-65,000.00","-137,000.00","-123,000.00","-123,497.00","-140,533.00","598,173.00","646,298.00","-516,948.00","-4,349,865.00","-739,658.00","-945,668.00","-676,149.00","-595,797.00","-11,161,018.00","-2,421,661.00","-3,557,390.00","-4,128,738.00","-347,767.00","5,656.00","-386,070.00","-517,098.00","-527,978.00","-679,539.00", 
DXB,Dimerix Limited,Annual Balance Sheet - Total Equity,"1,409,000.00","1,046,000.00","1,044,000.00","1,410,000.00","1,741,000.00","1,724,000.00","1,849,772.00","1,957,517.00","5,025,864.00","5,771,871.00","5,240,203.00","640,427.00","282,886.00","-565,025.00","-170,377.00","10,280,504.00","2,694,481.00","1,414,772.00","1,008,159.00","341,976.00","1,560,180.00","1,565,836.00","1,179,766.00","1,707,138.00","1,179,160.00","2,777,090.00", 
DXB,Dimerix Limited,Annual Balance Sheet - Total Assets,"1,727,000.00","1,149,000.00","1,161,000.00","1,636,000.00","2,033,000.00","1,981,000.00","2,243,534.00","2,260,732.00","9,689,631.00","9,121,446.00","7,901,573.00","2,278,158.00","1,890,609.00","1,216,200.00","1,827,671.00","10,521,001.00","3,038,236.00","4,071,529.00","2,448,607.00","385,333.00","1,606,528.00","1,593,823.00","1,214,290.00","1,753,446.00","1,213,655.00","2,968,733.00", 
EGX,EvoGenix Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-49.20%,-42.35%, , , , , , , , , , 
EGX,EvoGenix Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"528,451.00","440,089.00", , , , , , , , , , 
EGX,EvoGenix Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-2,862,278.00","-4,271,886.00", , , , , , , , , , 
EGX,EvoGenix Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"5,817,841.00","10,087,777.00", , , , , , , , , , 
EGX,EvoGenix Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"7,295,745.00","10,851,392.00", , , , , , , , , , 
FTT,Factor Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-0.25%,-8.18%,-24.20%,-35.61%,-25.69%,-129.43%,-121.28%,-43.90%,-31.35%,-64.67%,-41.09%,-40.51%,-84.19%, 
FTT,Factor Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,--,0.00,"5,873.00","9,611.00","37,144.00","80,732.00","252,948.00","229,484.00","232,024.00","336,637.00",0.00,--,0.00, 
FTT,Factor Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-8,878.00","-181,281.00","-926,847.00","-1,861,242.00","-1,710,280.00","-4,865,418.00","-4,473,196.00","-3,486,399.00","-5,340,548.00","-6,769,382.00","-5,740,094.00","-6,829,591.00","-11,218,514.00", 
FTT,Factor Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"3,497,712.00","3,325,709.00","3,829,662.00","5,227,194.00","6,658,310.00","3,759,058.00","3,688,189.00","7,942,395.00","17,033,436.00","10,466,891.00","13,968,238.00","16,859,743.00","13,325,214.00", 
FTT,Factor Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"3,517,712.00","3,383,016.00","4,024,671.00","5,439,014.00","7,298,398.00","6,224,288.00","4,136,418.00","8,498,279.00","22,807,934.00","12,932,253.00","15,794,992.00","18,832,690.00","15,206,043.00", 
GBI,Genera Biosystems Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-109.84%,-23.14%,-32.94%,-42.46%,-36.41%,-53.31%,-79.86%,-102.92%, 
GBI,Genera Biosystems Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,0.00,"36,500.00","39,500.00","55,300.00","231,448.00","46,568.00","204,730.00","344,728.00", 
GBI,Genera Biosystems Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-3,239,917.00","-1,614,506.00","-2,486,813.00","-2,934,769.00","-2,087,566.00","-2,262,872.00","-2,461,958.00","-2,789,474.00", 
GBI,Genera Biosystems Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"6,528,938.00","5,899,532.00","6,977,378.00","7,549,351.00","6,911,184.00","5,733,233.00","4,244,670.00","3,082,748.00","2,710,210.00", 
GBI,Genera Biosystems Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"7,531,537.00","6,924,146.00","8,193,746.00","8,858,534.00","8,234,083.00","6,808,340.00","5,241,692.00","5,192,131.00","6,390,050.00", 
GEN,Genesis Research & Development Corporation Limited,Annual Ratio Analysis - ROE, , , , , , , , ,-94.19%,-442.18%,1.24%,-15.73%,-26.77%,-46.68%,-101.32%,-111.78%,34.33%,-58.49%,-559.49%,-68.43%,"1,469.40%",78.32%,31.02%, , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,0.00,0.00,0.00,"10,770,170.00","9,986,991.00","7,412,722.00",--,0.00,--,--,"24,257.00","468,674.00","645,357.00",0.00,"19,828.00", , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-3,439,204.00","-5,697,665.00","574,356.00","-7,778,230.00","-9,927,522.00","-11,113,833.00","-12,640,760.00","-6,663,553.00","2,974,322.00","-672,890.00","-6,302,802.00","-628,136.00","-1,494,951.00","-368,200.00","-187,975.00", , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"3,651,522.00","1,288,548.00","46,302,033.00","41,116,176.00","37,086,972.00","23,808,732.00","12,475,539.00","5,961,143.00","8,664,407.00","7,666,020.00","978,670.00","917,921.00","-101,738.00","-470,140.00","-605,964.00", , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,"5,307,945.00","6,022,790.00","55,942,167.00","47,371,163.00","42,415,907.00","25,624,289.00","13,631,161.00","6,612,180.00","9,194,900.00","8,369,737.00","1,457,967.00","1,249,797.00","269,531.00","81,399.00","22,208.00", , , , 
GIA,Giaconda Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,-16.84%,-18.35%,-150.54%,-27.47%,27.68%, , , , , , 
GIA,Giaconda Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,"35,740.00","3,000.00",0.00,"5,280.00",0.00, , , , , , 
GIA,Giaconda Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,"-942,768.00","-1,011,253.00","-2,821,415.00","-1,092,712.00","-1,307,633.00", , , , , , 
GIA,Giaconda Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"5,597,204.00","4,909,498.00","1,874,141.00","781,429.00","-415,767.00", , , , , , 
GIA,Giaconda Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"6,275,766.00","5,724,105.00","3,092,215.00","1,936,241.00","772,476.00", , , , , , 
GRO,GroPep Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,-3.82%,1.58%,0.18%,-9.89%,-4.81%,5.47%,25.22%,10.59%, , , , , , , , , , 
GRO,GroPep Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"2,155,646.00","2,066,654.00","6,317,866.00","7,063,000.00","8,953,000.00","8,793,000.00","10,939,000.00","14,868,000.00","14,325,000.00", , , , , , , , , , 
GRO,GroPep Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"255,067.00","-665,912.00","48,715.00","35,000.00","-6,894,000.00","-2,546,000.00","1,018,000.00","6,472,000.00","3,188,000.00", , , , , , , , , , 
GRO,GroPep Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,"17,416,048.00","3,086,328.00","19,032,000.00","19,722,000.00","17,228,000.00","18,601,000.00","25,663,000.00","30,112,000.00", , , , , , , , , , 
GRO,GroPep Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,"20,653,728.00","9,823,073.00","20,987,000.00","31,070,000.00","20,058,000.00","23,096,000.00","29,340,000.00","32,796,000.00", , , , , , , , , , 
GSS,Genetic Signatures Limited,Annual Ratio Analysis - ROE, , , ,1.32%,-4.28%,-71.80%, , , , , , , , , , , , , , , , , , ,0.00%,-37.68%, 
GSS,Genetic Signatures Limited,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,0.00, , , , , , , , , , , , , , , , , , ,--,"1,043,269.00", 
GSS,Genetic Signatures Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"229,000.00","-1,092,000.00","-5,753,000.00", , , , , , , , , , , , , , , , , , ,0.00,"-2,659,120.00", 
GSS,Genetic Signatures Limited,Annual Balance Sheet - Total Equity, , , ,"302,000.00","13,424,000.00","7,671,000.00", , , , , , , , , , , , , , , , , , ,"16,177,239.00","7,056,969.00", 
GSS,Genetic Signatures Limited,Annual Balance Sheet - Total Assets, , , ,"302,000.00","13,771,000.00","13,727,000.00", , , , , , , , , , , , , , , , , , ,"16,547,714.00","7,800,112.00", 
GTG,Genetic Technologies Limited,Annual Ratio Analysis - ROE,-134.05%,-185.11%,-14.98%,-21.30%,-18.23%,-29.17%,-6.93%,-5.52%,-5.27%,-0.91%,5.21%,-8.93%,-28.37%,-15.19%,-31.38%,-28.45%,-26.34%,-16.68%,-26.38%,-57.50%,-146.01%,13.44%,-73.00%,-164.93%,-554.04%,-53.84%, 
GTG,Genetic Technologies Limited,Annual Profit and Loss - Operating Revenue,"1,739,000.00","152,000.00","467,000.00","368,000.00","132,000.00","98,000.00",0.00,"197,910.00","206,487.00","287,810.00",800.00,"5,022,826.00","1,620,831.00","8,496,890.00","3,147,587.00","8,962,441.00","9,235,469.00","12,146,330.00","13,829,016.00","5,382,182.00","5,805,558.00","4,594,960.00","3,691,215.00","3,377,183.00","4,564,280.00","2,011,918.00", 
GTG,Genetic Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-848,000.00","-1,736,000.00","-721,000.00","-1,415,000.00","-1,478,000.00","-3,122,000.00","-533,211.00","-489,653.00","-3,614,390.00","-3,306,335.00","-2,809,410.00","-3,443,603.00","-8,888,430.00","-4,325,345.00","-10,467,207.00","-10,420,232.00","-7,908,123.00","-4,345,702.00","-5,451,638.00","-7,858,321.00","-9,355,209.00","901,341.00","-5,296,828.00","-9,349,483.00","-10,134,469.00","-8,810,170.00", 
GTG,Genetic Technologies Limited,Annual Balance Sheet - Total Equity,"514,000.00","685,000.00","4,813,000.00","6,643,000.00","8,108,000.00","7,775,000.00","7,696,630.00","16,707,515.00","13,093,125.00","9,731,336.00","7,577,124.00","38,067,754.00","31,136,174.00","27,276,860.00","34,224,047.00","36,959,339.00","30,242,139.00","26,102,809.00","20,785,073.00","14,112,045.00","5,717,696.00","6,813,995.00","14,402,642.00","5,758,287.00","1,827,519.00","18,959,248.00", 
GTG,Genetic Technologies Limited,Annual Balance Sheet - Total Assets,"1,507,000.00","837,000.00","5,620,000.00","6,928,000.00","8,422,000.00","8,310,000.00","7,715,653.00","16,891,696.00","13,221,096.00","9,791,802.00","8,847,013.00","39,685,822.00","33,000,907.00","30,245,002.00","38,880,305.00","43,475,157.00","33,716,907.00","29,449,027.00","24,094,578.00","17,977,731.00","8,279,572.00","8,922,354.00","16,441,751.00","8,319,527.00","6,729,199.00","20,719,732.00", 
HXL,Hexima Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , ,-8.98%,-39.10%,-26.10%, , , , , , 
HXL,Hexima Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , ,0.00,0.00,0.00, , , , , , 
HXL,Hexima Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , ,"-3,029,909.00","-11,276,023.00","-6,118,978.00", , , , , , 
HXL,Hexima Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , ,"33,748,698.00","28,837,495.00","23,447,105.00", , , , , , 
HXL,Hexima Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , ,"36,664,990.00","31,418,364.00","26,078,260.00", , , , , , 
IDT,IDT Australia Limited,Annual Ratio Analysis - ROE,3.38%,-23.52%,8.44%,16.08%,6.72%,6.88%,9.81%,11.05%,14.13%,24.97%,28.67%,18.06%,18.15%,15.99%,15.27%,15.34%,12.59%,17.99%,21.64%,18.75%,-5.23%,-0.79%,-6.53%,-20.57%,-25.93%,-7.63%, 
IDT,IDT Australia Limited,Annual Profit and Loss - Operating Revenue,"5,283,000.00","3,820,000.00","3,953,000.00","4,451,000.00","4,768,000.00","5,658,000.00","7,534,296.00","8,152,869.00","9,568,542.00","12,274,954.00","14,534,472.00","18,760,805.00","20,876,225.00","25,532,000.00","25,234,000.00","26,546,000.00","24,811,000.00","26,298,000.00","30,871,000.00","26,423,000.00","11,825,000.00","12,770,000.00","9,808,000.00","10,593,000.00","13,171,000.00","15,703,000.00", 
IDT,IDT Australia Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"88,000.00","-840,000.00","199,000.00","390,000.00","333,000.00","343,000.00","512,966.00","631,434.00","891,913.00","1,863,424.00","3,005,152.00","3,696,650.00","4,222,107.00","4,223,000.00","4,260,000.00","4,471,000.00","3,613,000.00","5,467,000.00","7,110,000.00","6,416,000.00","-1,577,000.00","-236,000.00","-1,837,000.00","-5,354,000.00","-6,626,000.00","-2,992,000.00", 
IDT,IDT Australia Limited,Annual Balance Sheet - Total Equity,"2,600,000.00","1,760,000.00","2,357,000.00","2,426,000.00","4,959,000.00","4,985,000.00","5,231,525.00","5,714,879.00","6,310,632.00","7,463,272.00","10,483,474.00","20,471,400.00","23,259,721.00","26,412,000.00","27,890,000.00","29,148,000.00","28,692,000.00","30,390,000.00","32,861,000.00","34,212,000.00","30,142,000.00","29,972,000.00","28,135,000.00","26,029,000.00","25,551,000.00","39,205,000.00", 
IDT,IDT Australia Limited,Annual Balance Sheet - Total Assets,"4,387,000.00","3,221,000.00","3,394,000.00","3,546,000.00","6,035,000.00","7,767,000.00","10,244,491.00","10,943,947.00","12,412,263.00","14,558,883.00","18,463,805.00","28,225,418.00","32,813,992.00","34,243,000.00","36,560,000.00","37,280,000.00","35,376,000.00","36,916,000.00","42,341,000.00","39,460,000.00","33,091,000.00","32,451,000.00","31,775,000.00","30,706,000.00","28,295,000.00","43,200,000.00", 
IIL,Innate Immunotherapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-61.33%,-107.61%,-123.48%
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,0.00,"30,309.00",0.00
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-4,495,458.00","-5,236,578.00","-4,943,000.00"
IIL,Innate Immunotherapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"11,235,000.00","9,772,478.00","4,866,037.00","4,003,000.00"
IIL,Innate Immunotherapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"11,426,000.00","10,176,209.00","5,318,933.00","5,034,000.00"
IMC,Immuron Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-12.71%,-22.37%,-20.78%,-26.87%,-25.37%,-28.83%,-19.21%,-68.74%,-170.86%,-270.00%,"1,419.89%",-56.66%,-149.80%,-112.08%,"-2,441.01%",-37.49%,-103.21%, 
IMC,Immuron Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"181,200.00","55,400.00","488,232.00","1,981,753.00","3,285,611.00","3,677,553.00","4,867,597.00","4,002,371.00","4,249,324.00","292,904.00","524,102.00","461,890.00","213,951.00","449,012.00","149,755.00","1,044,142.00","1,123,707.00", 
IMC,Immuron Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-690,957.00","-993,546.00","-1,553,517.00","-1,699,112.00","-1,279,584.00","-1,162,035.00","-1,333,389.00","-3,559,931.00","-3,281,236.00","-2,858,337.00","-2,317,814.00","-1,905,807.00","-2,595,179.00","-2,297,520.00","-3,539,117.00","-2,544,550.00","-3,447,951.00", 
IMC,Immuron Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"5,435,464.00","4,441,918.00","7,475,121.00","6,322,947.00","5,043,363.00","4,031,328.00","6,940,452.00","5,178,647.00","1,920,473.00","1,087,316.00","-184,871.00","3,363,291.00","1,732,379.00","2,049,981.00","144,986.00","6,786,945.00","3,340,839.00", 
IMC,Immuron Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"5,653,814.00","4,502,854.00","7,831,401.00","6,576,789.00","5,954,709.00","4,909,765.00","8,054,905.00","6,625,251.00","3,295,978.00","1,899,952.00","493,029.00","3,798,394.00","2,660,215.00","3,638,286.00","2,526,632.00","7,632,245.00","4,548,649.00", 
IMU,Imugene Limited,Annual Ratio Analysis - ROE, , , ,4.75%,-12.21%,-20.10%,-28.93%,-35.53%,-63.12%,-74.45%,-159.04%,"1,783.98%",59.70%,-7.67%,-38.95%,-20.74%,-33.85%,-49.03%,-40.92%,12.21%,-40.49%,9.88%,-97.28%,-82.67%,-31.43%,-28.02%, 
IMU,Imugene Limited,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,"188,000.00","278,000.00","385,000.00","463,000.00","385,000.00","338,694.00","114,239.00","1,291,796.00",0.00,0.00,0.00,0.00,"1,572.00",0.00,0.00,0.00,"4,454,056.00","235,912.00",0.00,0.00,0.00, 
IMU,Imugene Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"243,000.00","-875,000.00","-2,135,000.00","-4,244,000.00","-2,182,000.00","-4,546,000.00","-4,930,000.00","-4,419,408.00","-4,041,485.00","-782,385.00","-2,044,118.00","-2,115,675.00","-1,794,208.00","-2,187,219.00","-2,304,263.00","-1,910,925.00","650,286.00","-1,535,041.00","415,539.00","-3,133,433.00","-1,559,566.00","-2,115,964.00","-2,440,789.00", 
IMU,Imugene Limited,Annual Balance Sheet - Total Equity, , , ,"5,111,000.00","11,186,000.00","10,621,000.00","8,122,000.00","7,452,000.00","6,755,000.00","5,995,000.00","2,778,850.00","-226,543.00","792,831.00","7,443,323.00","5,431,668.00","8,652,660.00","6,462,381.00","4,699,818.00","4,670,062.00","5,326,348.00","3,791,307.00","4,206,846.00","1,073,413.00","1,886,466.00","6,732,242.00","7,732,003.00", 
IMU,Imugene Limited,Annual Balance Sheet - Total Assets, , , ,"5,698,000.00","11,313,000.00","11,926,000.00","9,249,000.00","8,693,000.00","7,891,000.00","6,893,000.00","3,681,938.00","2,440,544.00","844,390.00","8,144,089.00","6,015,962.00","9,064,183.00","7,268,421.00","5,260,368.00","5,163,427.00","5,763,066.00","4,098,681.00","4,687,123.00","1,318,387.00","2,584,495.00","8,631,475.00","9,114,718.00", 
IVQ,Invitrocue Limited,Annual Ratio Analysis - ROE, , , , , ,11.46%,-8.43%,7.44%,-23.15%,139.54%,95.09%,62.01%,29.46%,-141.03%,234.15%,-11.81%,939.07%,84.85%,56.57%,-153.56%,-11.36%,3.65%,2.49%,111.11%,77.22%,294.19%, 
IVQ,Invitrocue Limited,Annual Profit and Loss - Operating Revenue, , , , , ,"46,548,000.00","36,891,264.00","65,735,924.00","63,405,724.00","31,246,668.00","49,624,809.00","65,426,000.00","88,040,000.00","32,754,000.00","33,903,000.00","32,125,000.00","29,748,000.00","15,681,000.00","11,302,000.00","41,670.00",0.00,--,0.00,0.00,--,0.00, 
IVQ,Invitrocue Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"3,051,000.00","-918,161.00","1,720,097.00","-5,754,909.00","-45,770,554.00","10,054,455.00","9,409,000.00","7,006,000.00","-17,935,000.00","-40,932,000.00","-929,000.00","-10,527,000.00","-10,864,000.00","-16,435,000.00","12,325,409.00","431,203.00","-165,807.00","268,473.00","3,839,027.00","-580,805.00","-66,387.00", 
IVQ,Invitrocue Limited,Annual Balance Sheet - Total Equity, , , , , ,"26,612,000.00","24,299,428.00","30,027,399.00","28,291,448.00","-16,000,048.00","5,545,770.00","15,174,000.00","23,781,000.00","5,981,000.00","-16,029,000.00","7,869,000.00","-1,121,000.00","-12,804,000.00","-29,052,000.00","-4,809,594.00","-4,378,391.00","-4,544,198.00","-4,275,725.00","-150,698.00","-591,503.00","-176,510.00", 
IVQ,Invitrocue Limited,Annual Balance Sheet - Total Assets, , , , , ,"47,245,000.00","41,866,977.00","65,170,050.00","73,135,671.00","26,604,090.00","33,575,429.00","40,894,000.00","54,500,000.00","43,050,000.00","34,527,000.00","27,301,000.00","20,218,000.00","17,942,000.00","15,373,000.00","122,476.00",90.00,"11,448.00","1,382.00","14,302.00","71,424.00","74,138.00", 
IVX,Invion Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , ,0.00%,351.42%,638.53%,-92.15%,-46.89%,-67.76%,-190.10%, 
IVX,Invion Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , ,--,0.00,0.00,0.00,0.00,0.00,0.00, 
IVX,Invion Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , ,0.00,"-16,787,189.00","-13,679,994.00","-5,540,923.00","-5,174,080.00","-6,883,937.00","-13,041,233.00", 
IVX,Invion Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , ,"12,138,420.00","-4,776,893.00","-2,142,416.00","6,013,240.00","11,035,582.00","10,159,077.00","6,860,171.00", 
IVX,Invion Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , ,"24,317,189.00","4,487,629.00","4,729,684.00","6,828,763.00","16,249,871.00","14,730,618.00","16,099,289.00", 
LCT,Living Cell Technologies Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,--,162.79%,-194.46%,-391.12%,-427.26%,-58.94%,-110.79%,-90.94%,-100.52%,39.55%,-22.48%,-80.40%,-137.38%, 
LCT,Living Cell Technologies Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,0.00,"72,714.00","65,412.00","1,307.00","18,292.00","51,946.00","186,463.00","517,087.00","176,538.00","3,708,000.00","7,580,000.00","7,394,130.00","611,955.00", 
LCT,Living Cell Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-3,609.00","-10,307,766.00","-6,097,309.00","-6,819,611.00","-5,987,322.00","-6,794,037.00","-6,123,562.00","-5,674,059.00","-6,795,708.00","5,676,000.00","-2,979,000.00","-6,778,896.00","-7,043,402.00", 
LCT,Living Cell Technologies Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,--,"-1,325,415.00","3,135,554.00","1,743,610.00","1,401,328.00","11,527,248.00","5,527,390.00","6,239,622.00","6,760,236.00","14,353,000.00","13,252,000.00","8,431,577.00","5,126,863.00", 
LCT,Living Cell Technologies Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,--,"1,309,448.00","3,944,714.00","4,258,164.00","3,817,446.00","12,241,442.00","6,500,029.00","6,943,366.00","7,471,632.00","15,523,000.00","14,218,000.00","9,664,604.00","5,464,515.00", 
LIP,Lipa Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,--,--,56.90%,29.78%,16.01%,13.09%, , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,"33,338,000.00","53,791,000.00","77,826,579.00","82,352,000.00","77,894,000.00","87,990,000.00", , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,0.00,0.00,"9,541,663.00","10,143,000.00","5,868,000.00","5,109,000.00", , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,--,--,"16,770,442.00","34,065,000.00","36,642,000.00","39,016,000.00", , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,--,--,"49,960,625.00","70,969,000.00","81,875,000.00","86,150,000.00", , , , , , , , , 
MDC,Medlab Clinical Limited,Annual Ratio Analysis - ROE,2.02%,-100.16%,5.19%,21.43%,40.33%,26.24%,18.72%,17.78%,18.73%,23.93%,38.41%,-7.86%,7.02%, , , , , , , , , , , ,0.00%, , 
MDC,Medlab Clinical Limited,Annual Profit and Loss - Operating Revenue,"708,182,016.00","715,060,992.00","409,908,000.00","238,454,000.00","379,491,008.00","315,985,984.00","321,756,992.00","355,028,992.00","387,256,000.00","449,048,992.00","509,628,000.00","208,912,000.00","551,960,000.00", , , , , , , , , , , ,--, , 
MDC,Medlab Clinical Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"1,855,000.00","-71,762,000.00","158,000.00","-2,463,000.00","-3,409,000.00","25,448,000.00","8,758,000.00","11,174,000.00","15,055,000.00","21,071,000.00","19,013,000.00","-3,932,000.00","5,729,000.00", , , , , , , , , , , ,0.00, , 
MDC,Medlab Clinical Limited,Annual Balance Sheet - Total Equity,"74,460,992.00","22,236,016.00","26,963,000.00","21,193,000.00","13,344,000.00","46,140,000.00","51,504,000.00","62,855,000.00","76,251,000.00","84,682,000.00","100,017,000.00","101,194,000.00","97,150,000.00", , , , , , , , , , , ,"10,458,130.00", , 
MDC,Medlab Clinical Limited,Annual Balance Sheet - Total Assets,"340,845,000.00","211,817,000.00","88,879,000.00","118,617,000.00","134,882,000.00","150,975,000.00","159,220,000.00","177,684,000.00","202,208,000.00","210,309,000.00","244,886,000.00","249,784,000.00","255,560,000.00", , , , , , , , , , , ,"11,033,603.00", , 
MEB,Medibio Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,-1.43%,-27.19%,-61.97%,-39.49%,-31.97%,-33.39%,-34.44%,-75.98%,-82.06%,-123.33%,-247.50%,-273.46%,-136.11%,-43.21%,-15.80%,-39.68%, 
MEB,Medibio Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,"140,719.00","155,375.00","57,590.00","36,755.00","113,053.00","17,159.00","8,356.00",0.00,--,"1,456.00","294,042.00","52,397.00","19,230.00",0.00,0.00, 
MEB,Medibio Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"-108,092.00","-1,882,228.00","-4,482,733.00","-3,381,332.00","-2,282,838.00","-1,828,453.00","-777,877.00","-1,429,844.00","-4,657,171.00","-3,035,460.00","-3,301,454.00","-3,220,121.00","-3,326,955.00","-1,096,713.00","-428,332.00","-7,921,702.00", 
MEB,Medibio Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"7,552,912.00","6,047,687.00","6,051,096.00","5,150,325.00","4,857,705.00","4,436,495.00","2,258,400.00","1,881,778.00","5,675,610.00","2,461,300.00","1,097,552.00","1,177,537.00","2,444,327.00","2,538,153.00","2,710,271.00","9,111,081.00", 
MEB,Medibio Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"8,142,538.00","6,999,481.00","6,963,638.00","5,437,908.00","5,134,661.00","4,676,083.00","2,442,382.00","2,061,596.00","6,172,678.00","2,723,535.00","1,408,569.00","3,276,813.00","5,476,283.00","5,418,911.00","5,042,517.00","15,184,514.00", 
MEM,Memphasys Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-274.83%,-499.04%,687.96%,25.63%,-3.79%,-71.54%,-147.92%,160.03%,-306.55%, 
MEM,Memphasys Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,"660,000.00","1,311,678.00","1,625,743.00","1,589,911.00","1,081,093.00","1,780,350.00","918,654.00","850,855.00","189,630.00", 
MEM,Memphasys Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-4,947,000.00","-5,496,190.00","-2,741,323.00","3,291,709.00","-6,321,097.00","-6,308,215.00","-1,841,920.00","-3,842,140.00","-2,645,684.00", 
MEM,Memphasys Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"1,800,000.00","1,101,357.00","-398,471.00","12,843,038.00","6,995,083.00","4,562,379.00","6,990,106.00","-992,848.00","746,591.00", 
MEM,Memphasys Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"4,463,000.00","5,055,784.00","5,756,596.00","17,717,066.00","10,571,264.00","8,951,867.00","13,632,034.00","7,102,391.00","6,844,468.00", 
MMJ,MMJ Phytotech Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-181.14%, 
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,--, 
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-4,882,396.00", 
MMJ,MMJ Phytotech Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"4,904,186.00","3,593,879.00", 
MMJ,MMJ Phytotech Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"4,961,432.00","3,814,571.00", 
MSB,Mesoblast Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-7.92%,-69.36%,-42.49%,-38.38%,-47.64%,-38.98%,-2.13%,-14.86%,-9.78%,-14.60%,-19.59%, 
MSB,Mesoblast Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,--,"27,712.00","727,531.00",--,0.00,0.00,"29,483,085.00","27,682,896.00","18,260,000.00","16,410,000.00","20,483,000.00", 
MSB,Mesoblast Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-1,517,141.00","-8,298,587.00","-8,728,131.00","-10,062,379.00","-12,285,459.00","-14,780,895.00","90,606,590.00","-71,145,314.00","-61,663,000.00","-80,958,000.00","-119,368,000.00", 
MSB,Mesoblast Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"20,812,400.00","19,150,467.00","11,965,045.00","20,539,339.00","26,216,132.00","25,789,962.00","37,919,260.00","515,844,173.00","478,847,783.00","630,266,000.00","571,718,000.00","609,359,000.00", 
MSB,Mesoblast Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"24,595,191.00","21,353,535.00","16,384,515.00","21,238,238.00","27,788,902.00","26,975,012.00","39,514,770.00","763,250,507.00","720,455,550.00","883,712,000.00","899,314,000.00","1,017,925,000.00", 
MVF,Monash IVF Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,3.72%,16.55%, 
MVF,Monash IVF Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,"114,012,000.00","121,913,000.00", 
MVF,Monash IVF Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,"4,852,000.00","21,373,000.00", 
MVF,Monash IVF Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"124,820,000.00","144,025,000.00", 
MVF,Monash IVF Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"246,358,000.00","283,789,000.00", 
MVP,Medical Developments International Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,5.74%,2.00%,8.07%,10.95%,7.55%,6.86%,6.91%,12.06%,16.72%,14.67%,5.53%,8.78%, 
MVP,Medical Developments International Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"5,475,000.00","3,048,000.00","5,404,000.00","6,605,000.00","7,460,000.00","9,219,000.00","8,727,000.00","8,296,000.00","10,206,000.00","11,313,000.00","11,733,000.00","9,370,000.00","11,608,000.00", 
MVP,Medical Developments International Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"481,000.00","168,000.00","797,000.00","1,207,000.00","891,000.00","810,000.00","879,000.00","1,743,000.00","2,704,000.00","2,309,000.00","875,000.00","1,529,000.00", 
MVP,Medical Developments International Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"7,502,000.00","8,374,000.00","8,400,000.00","9,872,000.00","11,021,000.00","11,801,000.00","11,814,000.00","12,712,000.00","14,455,000.00","16,169,000.00","15,744,000.00","15,824,000.00","17,407,000.00", 
MVP,Medical Developments International Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"11,633,000.00","12,472,000.00","11,555,000.00","12,499,000.00","12,115,000.00","13,189,000.00","13,392,000.00","14,215,000.00","16,713,000.00","19,136,000.00","20,259,000.00","22,560,000.00","22,988,000.00", 
MXC,MGC Pharmaceuticals Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,-7.46%,-97.38%,"22,108.98%",101.61%,-23.52%,-36.94%,-9.65%,-114.68%,-197.10%, 
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,0.00,0.00,"334,065.00","703,326.00",0.00,0.00,--,0.00,--, 
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"-284,396.00","-1,886,078.00","-1,945,590.00","-3,180,089.00","1,935,168.00","-290,880.00","-766,897.00","-5,337,815.00","-3,797,791.00", 
MXC,MGC Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"2,762,327.00","3,814,118.00","1,936,790.00","-8,790.00","-3,138,329.00","828,302.00","787,422.00","7,944,781.00","4,549,136.00","1,926,812.00", 
MXC,MGC Pharmaceuticals Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"5,370,386.00","4,791,321.00","2,640,695.00","16,419,629.00","14,131,700.00","1,093,823.00","992,363.00","8,703,770.00","4,978,430.00","2,520,603.00", 
MYP,Mayne Pharma Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%,4.75%, , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,"792,009,000.00", , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00,"-31,335,000.00", , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"1,660,588,000.00","1,751,022,000.00", , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"1,908,754,000.00","2,008,342,000.00", , , , , , , , , , 
MYX,Mayne Pharma Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-12.57%,-30.36%,-48.82%,12.73%,11.10%,13.58%,5.14%,11.63%,4.14%, 
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,--,0.00,"35,427,602.00","48,504,000.00","50,897,000.00","82,262,000.00","142,181,000.00","140,324,000.00", 
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-1,823,975.00","-3,472,806.00","-3,761,318.00","3,253,119.00","1,679,000.00","6,153,000.00","-2,843,000.00","21,290,000.00","7,537,000.00", 
MYX,Mayne Pharma Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"14,514,302.00","11,438,427.00","7,704,263.00","25,549,756.00","24,174,000.00","30,600,000.00","120,889,000.00","159,274,000.00","322,202,000.00", 
MYX,Mayne Pharma Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"15,510,458.00","11,693,279.00","8,035,794.00","71,149,412.00","53,677,000.00","53,933,000.00","233,391,000.00","265,820,000.00","528,946,000.00", 
NEU,Neuren Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,--,--,-65.18%,-41.78%,-62.65%,-160.95%,-276.70%,1.33%,-136.92%,-48.96%,-78.56%,-46.01%,-42.99%,-93.02%, 
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,"2,121,352.00","2,835,768.00","1,516,522.00","429,665.00","172,967.00","944,160.00","2,274,362.00","5,003,237.00","4,648,090.00",0.00,0.00,0.00,0.00,0.00, 
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,"-5,458,093.00","-5,647,038.00","-5,694,111.00","-8,308,425.00","-10,115,905.00","-12,152,545.00","-15,419,489.00","-26,711.00","-4,990,509.00","-4,740,966.00","-5,190,355.00","-11,336,519.00","-8,316,000.00","-13,397,000.00", 
NEU,Neuren Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,--,--,"8,735,462.00","19,884,177.00","16,146,576.00","7,550,642.00","5,572,563.00","7,348,227.00","3,533,520.00","9,453,023.00","6,340,418.00","24,355,179.00","19,078,000.00","14,402,000.00", 
NEU,Neuren Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,--,--,"12,961,971.00","35,204,558.00","19,523,894.00","14,586,048.00","8,544,542.00","10,284,927.00","5,717,105.00","11,136,553.00","8,481,916.00","26,413,273.00","22,106,000.00","16,904,000.00", 
NRT,Novogen Limited,Annual Ratio Analysis - ROE, , , , , ,-4.29%,-6.70%,-8.18%,-54.07%,-36.06%,0.00%,-37.87%,-27.50%,-24.99%,-16.86%,-19.61%,-38.22%,-49.25%,-66.03%,-79.94%,-110.33%,-188.34%,-175.05%,-43.42%,-494.27%,-15.98%, 
NRT,Novogen Limited,Annual Profit and Loss - Operating Revenue, , , , , ,"40,000.00","45,000.00","5,000.00","5,084,000.00","19,782,000.00","23,407,000.00","27,260,000.00","19,582,000.00","19,630,000.00","12,720,000.00","13,404,000.00","13,500,000.00","12,515,000.00","9,537,000.00","8,336,000.00","7,985,000.00","1,716,000.00","1,162,000.00","1,067,319.00",0.00,0.00, 
NRT,Novogen Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-555,000.00","-1,027,000.00","-2,304,000.00","-12,576,000.00","-17,409,000.00","-13,679,000.00","-21,764,000.00","-14,673,000.00","-10,666,000.00","-12,579,000.00","-12,281,000.00","-17,913,000.00","-24,296,000.00","-24,777,000.00","-23,787,000.00","-15,246,000.00","-9,479,000.00","-1,350,000.00","-784,560.00","-7,568,725.00","-7,306,045.00", 
NRT,Novogen Limited,Annual Balance Sheet - Total Equity, , , , , ,"12,945,000.00","15,341,000.00","28,174,000.00","23,004,000.00","48,275,000.00","52,724,000.00","51,906,000.00","54,045,000.00","42,397,000.00","69,211,000.00","60,492,000.00","44,578,000.00","44,626,000.00","35,637,000.00","28,773,000.00","13,176,000.00","4,420,000.00","5,113,000.00","4,040,802.00","1,412,034.00","44,362,053.00", 
NRT,Novogen Limited,Annual Balance Sheet - Total Assets, , , , , ,"13,608,000.00","18,511,000.00","32,348,000.00","28,584,000.00","56,796,000.00","65,018,000.00","61,206,000.00","61,900,000.00","50,812,000.00","77,413,000.00","67,485,000.00","51,098,000.00","51,357,000.00","43,401,000.00","37,842,000.00","19,290,000.00","12,727,000.00","8,985,000.00","5,748,194.00","4,659,097.00","46,139,441.00", 
OBJ,OBJ Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,0.00%,16.40%,-170.71%,-827.21%,129.89%,-11.04%,-100.45%,-249.36%,-75.22%,-81.76%,-410.33%,-18.93%,-20.02%,-42.75%,-41.35%,-57.59%,-66.08%, 
OBJ,OBJ Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"4,711,000.00","6,594,781.00",0.00,"4,162,950.00","2,011,703.00",0.00,0.00,--,"119,492.00","750,396.00","406,340.00","774,408.00","601,346.00","519,077.00","673,159.00","806,691.00","1,394,623.00", 
OBJ,OBJ Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,0.00,"1,473,000.00","-5,664,345.00","-2,960,305.00","-1,555,048.00","721,109.00","-1,234,506.00","-1,433,090.00","-1,396,511.00","-925,519.00","-1,732,579.00","-954,931.00","-897,529.00","-1,411,442.00","-1,331,572.00","-2,205,354.00","-2,353,454.00", 
OBJ,OBJ Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"7,368,000.00","8,982,432.00","3,318,172.00","357,867.00","-1,197,181.00","903,539.00","1,229,033.00","574,713.00","1,856,660.00","1,131,991.00","422,242.00","5,044,777.00","4,483,519.00","3,301,347.00","3,220,129.00","3,829,184.00","3,561,633.00", 
OBJ,OBJ Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"8,591,000.00","11,347,942.00","5,394,582.00","2,624,975.00","599,632.00","914,983.00","1,364,537.00","645,626.00","2,146,999.00","1,538,609.00","1,547,959.00","5,554,545.00","4,931,468.00","3,724,757.00","3,636,099.00","4,290,300.00","4,126,423.00", 
OCC,Orthocell Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%,"-5,728.42%",-85.38%, 
OCC,Orthocell Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,"691,405.00","790,430.00", 
OCC,Orthocell Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-2,182,185.00","-3,742,715.00", 
OCC,Orthocell Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"7,904,118.00","76,188.00","4,383,790.00", 
OCC,Orthocell Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"9,571,252.00","5,137,881.00","6,536,133.00", 
OPT,Opthea Limited,Annual Ratio Analysis - ROE,-32.72%,-8.74%,-8.84%,-17.62%,-17.02%,-22.77%,-22.39%,-26.26%,-45.76%,33.12%,-4.98%,-3.34%,-3.99%,-9.64%,13.92%,58.20%,-11.44%,-29.50%,-2.42%,-25.59%,-30.76%,-47.04%,-25.58%,-35.35%,-41.91%,-25.41%, 
OPT,Opthea Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"17,500.00","17,500.00",0.00,"22,554.00","15,000.00",0.00,0.00,0.00,0.00,0.00,0.00,0.00, 
OPT,Opthea Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-621,000.00","-181,000.00","-81,000.00","-511,000.00","-62,000.00","-665,000.00","-1,129,000.00","-1,403,969.00","-1,981,036.00","2,370,320.00","1,223,376.00","-1,623,000.00","-5,743,579.00","-3,506,768.00","5,802,611.00","21,764,179.00","-6,515,401.00","6,295,707.00","-2,286,119.00","-9,921,670.00","-6,948,240.00","-10,265,346.00","-4,906,456.00","-5,004,506.00","-3,989,618.00","-5,400,994.00", 
OPT,Opthea Limited,Annual Balance Sheet - Total Equity,"1,898,000.00","1,717,000.00","2,206,000.00","2,435,000.00","2,873,000.00","2,921,000.00","4,869,000.00","5,323,536.00","4,329,192.00","7,155,912.00","25,122,180.00","47,424,163.00","41,348,205.00","36,382,174.00","41,695,543.00","37,545,530.00","56,690,576.00","60,965,707.00","51,407,413.00","38,773,219.00","31,820,094.00","21,824,173.00","20,196,855.00","14,358,946.00","10,479,256.00","21,721,612.00", 
OPT,Opthea Limited,Annual Balance Sheet - Total Assets,"1,930,000.00","1,755,000.00","2,258,000.00","2,467,000.00","2,917,000.00","3,018,000.00","4,990,000.00","5,490,803.00","4,491,130.00","7,298,018.00","25,487,451.00","47,749,254.00","41,719,598.00","36,854,503.00","42,142,283.00","43,170,581.00","59,008,265.00","66,858,680.00","53,852,597.00","41,279,161.00","34,668,418.00","24,502,397.00","22,604,994.00","16,411,959.00","12,461,333.00","24,072,855.00", 
OSL,Oncosil Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-2.94%,-2.35%,-35.77%,-67.71%,-10.28%,-66.42%,-21.91%,-17.36%,-14.53%,-34.68%,-41.36%, 
OSL,Oncosil Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,"1,511,829.00","1,758,370.00","2,034,055.00","2,302,907.00","2,087,124.00",0.00,0.00,0.00,0.00,0.00, 
OSL,Oncosil Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-26,420.00","-128,266.00","-1,674,138.00","-2,767,299.00","-440,178.00","-1,712,021.00","-1,458,019.00","-430,970.00","-879,168.00","-4,217,103.00","-2,879,031.00", 
OSL,Oncosil Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"899,564.00","5,457,397.00","4,679,676.00","4,087,090.00","4,282,053.00","2,577,727.00","2,913,145.00","2,482,775.00","6,050,566.00","12,160,130.00","6,961,449.00", 
OSL,Oncosil Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"946,590.00","8,184,518.00","7,001,921.00","6,166,948.00","5,227,984.00","2,958,675.00","3,030,030.00","2,523,562.00","6,243,516.00","12,280,852.00","7,407,148.00", 
PAA,PharmAust Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-52.23%,-106.80%,-114.29%,-386.70%,-53.95%,-41.66%,-46.02%,-68.78%,-31.95%,-7.55%,-505.10%,-351.30%,-205.60%,-16.97%,-21.78%, 
PAA,PharmAust Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,--,"678,804.00","311,147.00","350,132.00","3,233,308.00","6,105,754.00","4,585,314.00","2,794,581.00","1,755,622.00","1,640,838.00","1,552,477.00","1,617,814.00","1,710,255.00","1,880,793.00","1,869,204.00", 
PAA,PharmAust Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-2,094,482.00","-3,705,897.00","-2,073,134.00","-2,584,719.00","-3,363,712.00","-2,752,284.00","-3,606,048.00","-5,767,973.00","-179,596.00","-438,600.00","-5,797,886.00","-4,260,420.00","-514,883.00","-1,317,853.00","-1,925,091.00", 
PAA,PharmAust Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"4,010,108.00","3,469,794.00","1,814,000.00","741,022.00","3,868,393.00","7,686,448.00","7,835,162.00","5,914,246.00","5,856,611.00","5,807,239.00","1,147,860.00","1,212,760.00","310,877.00","7,764,157.00","8,839,066.00", 
PAA,PharmAust Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"4,989,908.00","4,925,787.00","2,512,494.00","904,885.00","5,274,665.00","9,169,658.00","10,168,022.00","7,992,603.00","7,570,230.00","6,827,622.00","1,450,806.00","2,408,664.00","905,421.00","8,209,633.00","9,522,285.00", 
PAB,Patrys Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-31.88%,-48.89%,-49.47%,-55.12%,-41.05%,-32.76%,-58.62%,-78.38%, 
PAB,Patrys Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,--,"3,735.00","4,654.00","7,599.00","4,851.00","2,643.00",0.00,0.00, 
PAB,Patrys Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-7,323,602.00","-8,662,339.00","-7,535,123.00","-7,421,670.00","-5,108,891.00","-3,529,095.00","-7,289,090.00","-8,470,382.00", 
PAB,Patrys Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"818,810.00","22,975,675.00","17,717,576.00","15,232,766.00","13,465,487.00","12,445,818.00","10,772,602.00","12,434,269.00","3,970,340.00", 
PAB,Patrys Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"818,810.00","23,857,975.00","19,177,243.00","16,306,876.00","14,846,227.00","13,362,175.00","11,853,845.00","14,813,698.00","4,772,623.00", 
PAR,Paradigm Biopharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
PAR,Paradigm Biopharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"14,464,259.00", 
PAR,Paradigm Biopharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"15,041,584.00", 
PBP,Probiotec Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,13.09%,14.31%,17.02%,12.91%,10.47%,3.57%,2.32%,1.47%,-6.79%, 
PBP,Probiotec Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,"53,991,931.00","66,138,816.00","87,146,623.00","75,040,646.00","71,770,144.00","66,046,188.00","67,342,884.00","68,214,622.00","65,679,685.00", 
PBP,Probiotec Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"4,977,524.00","6,309,098.00","8,900,922.00","9,480,874.00","-10,337,787.00","1,249,380.00","596,869.00","903,668.00","-24,742,302.00", 
PBP,Probiotec Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"30,535,000.00","38,022,400.00","44,079,844.00","52,284,179.00","73,453,476.00","61,315,353.00","62,474,150.00","63,519,089.00","64,320,407.00","39,631,155.00", 
PBP,Probiotec Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"63,911,000.00","77,914,121.00","85,905,143.00","102,258,413.00","126,247,372.00","106,561,756.00","101,165,392.00","109,862,566.00","104,490,677.00","73,007,404.00", 
PBT,Prana Biotechnology Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-0.36%,-6.40%,-19.35%,-32.69%,-28.97%,-25.54%,-127.63%,-134.25%,-198.54%,-137.44%,-200.62%,-93.83%,-92.79%,-93.17%,-55.72%,-35.37%,-15.05%, 
PBT,Prana Biotechnology Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,--,"226,000.00","567,250.00",238.00,0.00,"6,286.00","1,050,286.00",0.00,170.00,--,--,0.00,0.00,0.00,0.00,0.00, 
PBT,Prana Biotechnology Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-80,000.00","-1,326,000.00","-4,138,979.00","-5,448,467.00","-4,584,838.00","-9,885,614.00","-25,008,597.00","-11,719,309.00","-11,142,320.00","-13,560,678.00","-7,522,789.00","-4,906,922.00","-6,431,185.00","-5,239,469.00","-7,787,242.00","-13,329,239.00","-5,885,069.00", 
PBT,Prana Biotechnology Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"21,961,232.00","20,729,307.00","21,392,877.00","16,668,986.00","15,823,703.00","38,702,559.00","19,594,176.00","8,729,350.00","5,612,195.00","9,866,327.00","3,749,816.00","5,229,316.00","6,931,202.00","5,623,447.00","13,974,713.00","37,686,287.00","39,113,264.00", 
PBT,Prana Biotechnology Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"21,961,232.00","20,876,444.00","22,314,743.00","17,581,319.00","16,389,926.00","41,415,398.00","22,289,159.00","10,421,146.00","7,722,185.00","11,698,313.00","4,597,250.00","6,801,417.00","9,010,952.00","7,341,868.00","17,073,821.00","41,640,855.00","41,834,382.00", 
PIQ,Proteomics International Laboratories Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-63.66%, 
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"608,394.00", 
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-1,149,202.00", 
PIQ,Proteomics International Laboratories Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"4,940,699.00","1,805,285.00", 
PIQ,Proteomics International Laboratories Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"5,234,394.00","2,532,298.00", 
PLI,Peplin Inc.,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-160.08%,"-2,361.23%", , , , , , , 
PLI,Peplin Inc.,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"43,044.00","19,462.00", , , , , , , 
PLI,Peplin Inc.,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-26,964,728.00","-54,064,158.00", , , , , , , 
PLI,Peplin Inc.,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"23,255,719.00","16,844,724.00","2,289,663.00", , , , , , , 
PLI,Peplin Inc.,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"28,382,809.00","37,366,607.00","28,794,068.00", , , , , , , 
PNM,Pallane Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-19.55%,-101.66%,-167.19%,249.25%,79.89%, , , , , , , 
PNM,Pallane Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,"533,686.00",--,--,--,400.00, , , , , , , 
PNM,Pallane Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-997,786.00","-2,299,330.00","-2,846,609.00","-3,100,496.00","-3,432,208.00", , , , , , , 
PNM,Pallane Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"5,312,282.00","5,104,147.00","2,261,715.00","1,702,603.00","-1,243,953.00","-4,296,393.00", , , , , , , 
PNM,Pallane Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"5,341,161.00","5,193,006.00","2,894,620.00","1,884,715.00","973,389.00","1,289,291.00", , , , , , , 
PNO,PharmaNet Group Limited,Annual Ratio Analysis - ROE,-17.06%,-95.97%,14.56%,10.02%,350.00%,-61.23%,"-68,938.28%",100.38%,142.68%,-18.65%,-28.14%,-60.82%,-53.22%,-78.85%,"-1,709.54%",35.22%,229.23%,203.28%,215.25%,90.93%,-236.30%,-629.93%,-209.76%,-21.18%,65.49%, , 
PNO,PharmaNet Group Limited,Annual Profit and Loss - Operating Revenue,"74,000.00","48,000.00","43,000.00","54,000.00","36,000.00","52,000.00","31,404.00","32,444.00","23,373.00","13,793.00","14,819.00","18,330.00","8,633.00","12,361.00","3,816,037.00","5,484,374.00","2,497.00","89,032.00",0.00,0.00,0.00,"140,402.00","201,024.00","813,049.00","204,603.00", , 
PNO,PharmaNet Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-496,000.00","-2,485,000.00","-1,040,000.00","-41,000.00","-126,000.00","-169,000.00","-275,621.00","-75,635.00","-238,120.00","-1,608,802.00","-2,791,416.00","-3,907,548.00","-2,033,631.00","-698,584.00","-2,092,887.00","-833,690.00","-3,546,889.00","-1,157,963.00","-937,706.00","-948,860.00","-1,075,790.00","-1,507,621.00","-2,146,826.00","-2,245,884.00","-2,158,897.00", , 
PNO,PharmaNet Group Limited,Annual Balance Sheet - Total Equity,"2,907,000.00","422,000.00","-618,000.00","-659,000.00","-36,000.00","276,000.00",290.00,"-75,345.00","-144,965.00","3,234,316.00","7,182,949.00","3,455,400.00","1,749,951.00","1,071,367.00","122,424.00","1,824,533.00","-730,796.00","-569,643.00","-429,823.00","-1,072,093.00","417,891.00","211,448.00","99,475.00","-1,236,359.00","-3,410,278.00", , 
PNO,PharmaNet Group Limited,Annual Balance Sheet - Total Assets,"3,712,000.00","1,206,000.00","162,000.00","139,000.00","778,000.00","391,000.00","98,208.00","75,411.00","32,175.00","3,796,749.00","7,559,508.00","4,045,633.00","1,977,715.00","1,250,564.00","2,335,448.00","2,727,131.00","972,283.00","566,107.00","705,842.00","561,869.00","2,175,552.00","2,383,392.00","2,096,343.00","856,339.00","236,573.00", , 
PNV,Polynovo Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-24.58%,-31.10%,-79.13%,-34.83%,-136.88%,-57.20%,-62.29%,-49.61%,-64.49%,-26.98%,-12.55%,-13.54%,-27.32%,-33.62%,-18.98%,-33.68%,-36.79%, 
PNV,Polynovo Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"222,572.00",0.00,0.00,--,0.00,836.00,0.00,178.00,"4,366.00",0.00,0.00,"121,910.00","388,201.00",0.00,0.00,"55,375.00","3,000.00", 
PNV,Polynovo Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-1,635,642.00","-3,563,405.00","-5,071,000.00","-5,731,276.00","-8,570,079.00","-9,543,526.00","-10,764,589.00","-11,293,869.00","-13,406,939.00","-4,441,167.00","-1,830,175.00","-2,305,353.00","-2,944,402.00","-2,702,726.00","-1,497,555.00","-2,941,975.00","-1,414,321.00", 
PNV,Polynovo Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"6,655,299.00","11,458,422.00","6,408,197.00","12,148,571.00","6,261,207.00","16,684,516.00","17,281,740.00","22,764,614.00","20,788,032.00","16,461,066.00","15,822,858.00","13,741,844.00","10,640,479.00","7,988,617.00","7,817,880.00","8,668,011.00","7,393,306.00", 
PNV,Polynovo Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"7,077,935.00","11,962,309.00","7,222,797.00","12,614,331.00","7,474,346.00","18,651,033.00","18,686,235.00","24,948,501.00","22,017,251.00","17,162,756.00","17,287,778.00","15,021,442.00","11,771,471.00","8,909,102.00","8,618,688.00","9,413,718.00","8,125,790.00", 
POH,Phosphagenics Limited,Annual Ratio Analysis - ROE, , , ,-8.70%,9.76%,-21.97%,-11.39%,-398.12%,-243.28%,10.02%,-5.68%,-14.09%,-29.37%,-9.06%,-2.78%,-5.54%,-4.52%,-6.61%,23.97%,-17.01%,-28.91%,1.52%,-17.66%,-33.39%,-19.16%,-38.15%, 
POH,Phosphagenics Limited,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"139,014.00",0.00,0.00,"184,000.00","1,379,000.00","1,586,000.00","2,508,000.00","670,000.00","4,660,000.00","2,516,000.00","1,284,000.00","1,376,000.00","2,053,000.00","1,880,000.00", 
POH,Phosphagenics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"816,000.00","-341,000.00","17,622,000.00","-3,096,184.00","-21,692,944.00","-3,861,570.00","503,571.00","-1,174,000.00","-5,365,120.00","-4,348,764.00","-2,661,601.00","-3,148,261.00","-7,323,000.00","-6,125,000.00","-8,844,000.00","-91,206,000.00","-8,501,000.00","-11,275,000.00","1,106,000.00","-11,055,000.00","-12,673,000.00","-8,935,000.00","-20,120,000.00", 
POH,Phosphagenics Limited,Annual Balance Sheet - Total Equity, , , ,"10,416,000.00","10,813,000.00","28,903,000.00","27,175,053.00","5,448,883.00","1,587,313.00","5,024,114.00","20,674,736.00","18,340,983.00","14,808,464.00","29,383,188.00","113,222,855.00","132,184,000.00","135,474,000.00","133,762,000.00","51,553,000.00","49,989,000.00","39,007,000.00","72,946,000.00","62,612,000.00","40,771,000.00","49,028,000.00","28,928,000.00", 
POH,Phosphagenics Limited,Annual Balance Sheet - Total Assets, , , ,"11,875,000.00","11,193,000.00","34,482,000.00","33,010,823.00","5,522,365.00","1,620,477.00","5,096,276.00","20,859,986.00","18,397,402.00","14,838,814.00","29,408,306.00","114,033,586.00","171,072,000.00","173,494,000.00","171,521,000.00","69,189,000.00","67,364,000.00","53,768,000.00","76,577,000.00","64,121,000.00","42,958,000.00","50,901,000.00","30,744,000.00", 
PRR,Prima BioMed Limited,Annual Ratio Analysis - ROE,-3.32%,-6.67%,-51.87%,10.34%,-0.83%,-2.39%,-61.89%,-242.63%,-32.84%,-18.73%,-37.51%,-25.22%,-69.15%,-140.14%,-98.07%,-74.60%,-67.34%,-76.94%,-71.67%,-162.53%,-60.90%,-38.26%,-53.67%,-52.06%,-59.06%,-130.22%, 
PRR,Prima BioMed Limited,Annual Profit and Loss - Operating Revenue,"34,000.00","7,000.00","103,000.00","832,000.00","1,514,000.00","1,663,000.00","2,679,250.00","658,707.00","47,841.00",0.00,--,--,0.00,"2,501.00","211,003.00","403,095.00","86,738.00","130,345.00",--,--,0.00,"1,066,196.00","25,766.00",0.00,"15,929.00","168,322.00", 
PRR,Prima BioMed Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-43,000.00","-322,000.00","-333,000.00","74,000.00","-92,000.00","-278,000.00","-953,494.00","-1,551,964.00","286,359.00","-1,902,514.00","-703,845.00","-2,064,636.00","-3,965,058.00","-5,781,644.00","-5,664,015.00","-7,076,303.00","-4,357,874.00","-3,139,034.00","-1,887,378.00","-2,946,442.00","-12,159,115.00","-21,081,167.00","-19,940,960.00","-15,225,671.00","-13,343,381.00","-32,151,696.00", 
PRR,Prima BioMed Limited,Annual Balance Sheet - Total Equity,"1,297,000.00","975,000.00","642,000.00","716,000.00","2,424,000.00","2,470,000.00","1,355,184.00","399,480.00","677,541.00","2,199,245.00","1,876,400.00","4,142,832.00","5,460,409.00","3,093,448.00","5,126,211.00","8,343,101.00","6,316,598.00","4,080,070.00","2,633,433.00","1,812,522.00","16,787,514.00","55,099,130.00","37,157,871.00","29,248,418.00","22,592,320.00","24,689,743.00", 
PRR,Prima BioMed Limited,Annual Balance Sheet - Total Assets,"1,351,000.00","1,016,000.00","703,000.00","1,205,000.00","2,642,000.00","4,717,000.00","5,095,947.00","4,257,924.00","1,708,087.00","2,354,211.00","2,094,961.00","4,244,271.00","5,926,161.00","3,968,331.00","5,767,688.00","9,131,212.00","7,359,924.00","4,358,277.00","2,821,250.00","2,489,620.00","19,011,184.00","57,640,661.00","41,612,671.00","32,814,298.00","25,377,955.00","30,983,445.00", 
PSD,pSivida Limited,Annual Ratio Analysis - ROE,0.70%,3.14%,2.80%,11.50%,16.40%,4.81%,-14.55%,-35.11%, , ,0.00%,-19.47%,-27.59%,-45.37%,-10.00%,-18.41%,-16.09%,-42.02%, , , , , , , , , 
PSD,pSivida Limited,Annual Profit and Loss - Operating Revenue,"83,200,000.00","82,200,000.00","97,504,000.00","107,330,000.00","111,377,000.00","102,462,000.00","96,911,360.00","79,813,672.00", , ,--,--,0.00,--,0.00,0.00,"932,074.00","944,000.00", , , , , , , , , 
PSD,pSivida Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"136,000.00","-3,084,000.00","495,000.00","1,782,000.00","1,975,000.00","1,384,000.00","-6,727,154.00","-4,963,305.00", , ,0.00,"-851,730.00","-3,997,024.00","-5,356,328.00","-7,518,976.00","-15,125,719.00","-28,166,129.00","-122,258,000.00", , , , , , , , , 
PSD,pSivida Limited,Annual Balance Sheet - Total Equity,"15,695,000.00","12,419,000.00","13,374,000.00","14,452,000.00","15,174,000.00","26,288,000.00","19,561,264.00","14,597,959.00", , ,"9,743,000.00","8,962,130.00","10,712,821.00","6,299,519.00","38,428,943.00","79,987,614.00","175,032,585.00","77,720,000.00", , , , , , , , , 
PSD,pSivida Limited,Annual Balance Sheet - Total Assets,"43,910,000.00","40,223,000.00","38,123,000.00","40,266,000.00","42,124,000.00","48,923,000.00","45,167,926.00","38,231,073.00", , ,"10,069,000.00","9,247,729.00","11,273,860.00","7,175,342.00","40,367,058.00","82,035,313.00","235,486,077.00","101,554,000.00", , , , , , , , , 
PTX,Prescient Therapeutics Limited,Annual Ratio Analysis - ROE,27.78%,7.20%,-21.09%,105.86%,-392.56%,855.22%,"1,682.45%","-3,965.77%",-87.92%,-53.21%,-178.79%,-63.45%,-181.83%,-328.78%,-108.97%,-141.30%,-228.17%,-150.88%,"-2,427.65%",222.66%,-668.60%,163.65%,105.90%,--,-25.80%,-47.94%, 
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - Operating Revenue,"18,619,000.00","20,736,000.00","23,150,000.00","24,379,000.00","24,162,000.00","20,122,000.00","1,517,369.00",0.00,0.00,0.00,--,0.00,0.00,"154,046.00",0.00,0.00,"208,693.00","1,543,406.00","364,877.00",0.00,0.00,0.00,0.00,0.00,--,0.00, 
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"411,000.00","2,000.00","-203,000.00","-302,000.00","-1,437,000.00","-216,000.00","98,082.00","-1,307,255.00","-1,031,409.00","-1,424,998.00","-2,282,318.00","-2,293,200.00","-2,647,494.00","-3,135,288.00","-3,963,451.00","-3,998,826.00","-4,625,343.00","-2,667,326.00","-1,773,449.00","-1,345,933.00","-1,864,246.00","-1,361,594.00","-1,892,370.00","1,787,000.00","-1,296,896.00","-2,133,375.00", 
PTX,Prescient Therapeutics Limited,Annual Balance Sheet - Total Equity,"1,792,000.00","1,659,000.00","1,171,000.00","546,000.00","336,000.00","-134,000.00","-41,547.00","24,336.00","1,173,068.00","2,678,039.00","1,276,550.00","3,614,450.00","1,456,015.00","953,603.00","3,637,243.00","2,830,018.00","2,027,114.00","1,767,898.00","73,052.00","-604,478.00","278,829.00","-832,034.00","-1,787,000.00",0.00,"5,026,822.00","4,450,486.00", 
PTX,Prescient Therapeutics Limited,Annual Balance Sheet - Total Assets,"7,181,000.00","7,084,000.00","6,846,000.00","5,549,000.00","5,901,000.00","2,249,000.00","24,156.00","161,764.00","1,235,046.00","2,797,739.00","1,384,163.00","4,282,180.00","1,904,438.00","1,633,603.00","4,148,056.00","4,182,793.00","3,707,626.00","3,244,294.00","1,750,467.00","1,181,674.00","1,567,567.00","701,856.00","61,824.00",--,"5,279,715.00","4,891,614.00", 
PVA,pSivida Corp,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-251.58%,-10.67%,26.49%,-23.05%,-182.13%,-154.55%,-89.49%,27.16%, 
PVA,pSivida Corp,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"3,457,303.00","14,857,037.00","26,481,285.00","3,363,441.00",0.00,0.00,"3,686,836.00","34,589,843.00", 
PVA,pSivida Corp,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-78,610,014.00","-3,094,651.00","10,269,858.00","-8,034,267.00","-24,369,541.00","-12,830,188.00","-14,177,282.00","8,264,322.00", 
PVA,pSivida Corp,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"88,265,000.00","31,246,623.00","29,012,817.00","38,766,866.00","34,857,063.00","13,380,433.00","8,301,886.00","15,842,887.00","30,427,083.00", 
PVA,pSivida Corp,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"107,220,000.00","57,951,381.00","45,728,370.00","50,468,145.00","43,870,937.00","20,210,970.00","17,519,137.00","24,066,878.00","42,144,531.00", 
PVL,Provalis Plc,Annual Ratio Analysis - ROE,-4.81%,-16.15%,-14.28%,-16.90%,-12.43%,-9.64%,-4.37%,-13.89%,-70.59%,-234.33%,-426.39%,-49.06%, , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Profit and Loss - Operating Revenue,"7,700,000.00","5,317,000.00","8,139,000.00","10,513,000.00","9,755,000.00","13,491,000.00","17,483,000.00","13,734,000.00","19,729,730.00","22,721,660.00","16,236,867.00","21,648,626.00", , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Profit and Loss - Reported NPAT After Abnorma,"-4,716,000.00","-27,374,000.00","-18,567,000.00","-10,642,000.00","-10,537,000.00","-8,979,000.00","-7,932,000.00","-24,657,000.00","-48,648,649.00","-39,268,955.00","-42,761,006.00","-12,212,045.00", , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Balance Sheet - Total Equity,"115,371,000.00","64,474,000.00","83,090,000.00","66,851,000.00","84,284,000.00","82,578,000.00","180,559,000.00","177,736,000.00","81,351,351.00","16,547,296.00","10,028,653.00","29,419,927.00", , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Balance Sheet - Total Assets,"134,219,000.00","81,276,000.00","90,044,000.00","73,817,000.00","92,189,000.00","106,370,000.00","208,746,000.00","212,457,000.00","124,654,055.00","57,251,123.00","44,412,607.00","49,403,275.00", , , , , , , , , , , , , , , 
PVT,Provet Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , ,0.00%,11.14%, , , , , , 
PVT,Provet Holdings Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , ,--,"282,206,000.00", , , , , , 
PVT,Provet Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , ,0.00,"6,741,000.00", , , , , , 
PVT,Provet Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , ,"54,638,859.00","60,487,000.00", , , , , , 
PVT,Provet Holdings Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , ,"107,973,323.00","112,444,000.00", , , , , , 
PXS,Pharmaxis Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-5.03%,-22.41%,-28.77%,-17.93%,-31.58%,-17.16%,-25.54%,-40.29%,-64.60%,-35.19%,-64.12%,-286.81%,51.60%, 
PXS,Pharmaxis Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"41,441.00",0.00,500.00,"8,000.00","205,000.00","527,000.00","595,000.00","1,170,000.00","1,202,000.00","1,466,000.00","3,237,000.00","5,036,000.00","57,741,000.00", 
PXS,Pharmaxis Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-1,467,789.00","-6,000,669.00","-10,232,357.00","-17,733,000.00","-24,179,000.00","-20,440,000.00","-35,171,000.00","-46,345,000.00","-45,758,000.00","-38,644,000.00","-43,537,000.00","-51,818,000.00","18,466,000.00", 
PXS,Pharmaxis Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"29,190,061.00","26,780,231.00","35,568,726.00","98,888,000.00","76,559,000.00","119,121,000.00","137,691,000.00","115,016,000.00","70,830,000.00","109,803,000.00","67,895,000.00","18,067,000.00","36,321,000.00", 
PXS,Pharmaxis Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"29,794,556.00","28,261,020.00","37,937,437.00","104,267,000.00","82,648,000.00","125,049,000.00","163,997,000.00","140,767,000.00","94,572,000.00","131,700,000.00","112,280,000.00","66,747,000.00","82,558,000.00", 
PYC,Phylogica Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-27.46%,-188.78%,-177.03%,-166.40%,-234.97%,"1,046.22%",-82.83%,-144.94%,-287.87%,-87.60%,-310.95%, 
PYC,Phylogica Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"52,556.00",0.00,"275,385.00","90,752.00","1,274,942.00","596,256.00","2,358,532.00","1,918,368.00",0.00,"692,150.00","763,393.00", 
PYC,Phylogica Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-1,587,323.00","-3,991,475.00","-3,888,673.00","-4,483,938.00","-4,490,920.00","-4,572,825.00","-3,605,169.00","-3,904,524.00","-3,439,624.00","-3,257,695.00","-2,991,479.00", 
PYC,Phylogica Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"5,780,882.00","2,114,304.00","2,196,662.00","2,694,638.00","1,911,244.00","-437,080.00","4,352,723.00","2,693,858.00","1,194,873.00","3,718,659.00","962,034.00", 
PYC,Phylogica Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"6,084,495.00","2,832,213.00","3,533,984.00","3,519,002.00","3,487,221.00","1,570,040.00","5,661,077.00","3,495,024.00","2,262,461.00","4,524,135.00","1,785,839.00", 
QRX,QRxPharma Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-0.65%,-129.17%,-79.41%,-237.73%,-394.83%,-87.42%,-101.79%,-146.10%,-171.50%, 
QRX,QRxPharma Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,0.00,--,0.00,0.00,0.00,0.00,"4,156,000.00","592,000.00",0.00, 
QRX,QRxPharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-405,300.00","-36,602,000.00","-13,495,000.00","-27,474,000.00","-25,635,000.00","-16,045,000.00","-10,080,000.00","-13,341,000.00","-5,392,000.00", 
QRX,QRxPharma Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"61,980,473.00","28,337,000.00","16,995,000.00","11,779,000.00","6,527,000.00","18,198,000.00","9,847,000.00","9,070,000.00","2,812,000.00", 
QRX,QRxPharma Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"62,812,346.00","30,361,000.00","18,679,000.00","13,873,000.00","8,249,000.00","24,811,000.00","12,623,000.00","10,910,000.00","3,556,000.00", 
RAC,Race Oncology Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
RAC,Race Oncology Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
RAC,Race Oncology Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
RAC,Race Oncology Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"7,053,071.00", 
RAC,Race Oncology Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"7,112,543.00", 
RBC,Rubicon Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%, , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--, , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00, , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"250,280,763.00", , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"268,730,948.00", , , , , , , , , , , , , , , , 
RBY,Rockeby Biomed Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,-30.32%,-30.07%,-105.99%,-53.36%,-84.29%,-89.40%, , , , , , , 
RBY,Rockeby Biomed Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,"30,736.00","140,143.00","290,139.00","1,127,472.00","397,112.00","936,100.00", , , , , , , 
RBY,Rockeby Biomed Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-5,324,068.00","-4,703,955.00","-7,399,069.00","-4,031,542.00","-4,391,822.00","-2,955,688.00", , , , , , , 
RBY,Rockeby Biomed Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"17,557,420.00","15,644,624.00","6,980,973.00","7,554,947.00","5,210,165.00","3,306,110.00", , , , , , , 
RBY,Rockeby Biomed Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"18,683,523.00","16,412,582.00","11,294,223.00","12,177,446.00","9,669,323.00","8,468,135.00", , , , , , , 
RCE,Recce Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
RCE,Recce Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
RCE,Recce Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
RCE,Recce Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"4,714,110.00", 
RCE,Recce Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"4,986,581.00", 
RGS,Regeneus Ltd,Annual Ratio Analysis - ROE, , ,-6.48%,4.00%,0.64%,0.11%,-0.70%,-0.22%,11.67%,25.69%,19.34%,11.85%,-1.36%, , , , , , , , , ,0.00%, ,-60.37%,-79.86%, 
RGS,Regeneus Ltd,Annual Profit and Loss - Operating Revenue, , ,"3,484,000.00","4,782,000.00",0.00,0.00,0.00,0.00,"74,169,000.00","154,415,008.00","185,303,000.00","195,020,000.00","86,046,000.00", , , , , , , , , ,--, ,"998,036.00","1,820,353.00", 
RGS,Regeneus Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , ,"-669,000.00","1,082,000.00","18,211,000.00","-460,000.00","6,441,000.00","-168,000.00","23,448,000.00","16,117,000.00","30,057,000.00","21,652,000.00","-87,165,000.00", , , , , , , , , ,0.00, ,"-7,523,218.00","-6,606,521.00", 
RGS,Regeneus Ltd,Annual Balance Sheet - Total Equity, , ,"8,509,000.00","10,027,000.00","46,848,000.00","49,654,000.00","67,231,000.00","101,202,000.00","126,350,000.00","130,559,000.00","161,094,000.00","196,209,000.00","40,538,000.00", , , , , , , , , ,"15,704,000.00", ,"8,308,028.00","8,272,134.00", 
RGS,Regeneus Ltd,Annual Balance Sheet - Total Assets, , ,"14,319,000.00","13,249,000.00","55,535,000.00","52,022,000.00","77,777,000.00","171,144,000.00","290,516,000.00","281,417,000.00","289,365,000.00","325,409,000.00","50,204,000.00", , , , , , , , , ,"16,733,000.00", ,"10,259,054.00","9,579,261.00", 
RHS,Reproductive Health Science Limited,Annual Ratio Analysis - ROE,-0.35%,-11.25%,-4.58%,-3.70%,-1.90%,-1.51%,-7.30%,-10.65%,-14.30%,-11.44%,-36.45%,-17.39%,-30.49%,-51.44%,300.08%,151.81%,-257.72%,-7.89%,-17.43%,-9.36%,-287.25%,-26.05%,-391.42%,-322.75%,-342.98%,-121.09%, 
RHS,Reproductive Health Science Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"1,382,813.00","6,215,000.00","8,672,000.00","858,091.00",--,"12,000.00",--,--,--,0.00,--,0.00,0.00,"73,363.00", 
RHS,Reproductive Health Science Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-18,000.00","-514,000.00","-200,000.00","-160,000.00","-227,000.00","-111,000.00","-3,128,497.00","-1,573,694.00","-508,988.00","-453,617.00","-1,467,360.00","-724,177.00","-2,004,696.00","-4,260,000.00","-16,806,000.00","-49,074.00","-1,697,323.00","-331,961.00","-781,645.00","-880,921.00","-6,972,361.00","-585,134.00","-3,291,616.00","-1,474,578.00","-6,091,210.00","-1,635,179.00", 
RHS,Reproductive Health Science Limited,Annual Balance Sheet - Total Equity,"5,081,000.00","4,567,000.00","4,367,000.00","4,085,000.00","5,482,000.00","6,216,000.00","3,228,512.00","2,601,998.00","3,558,570.00","3,964,729.00","4,025,969.00","4,163,427.00","6,764,501.00","8,282,000.00","-1,305,000.00","-1,368,407.00","1,317,177.00","4,209,742.00","4,484,269.00","9,412,174.00","2,427,295.00","2,192,944.00","504,865.00","456,874.00","1,735,310.00","1,350,384.00", 
RHS,Reproductive Health Science Limited,Annual Balance Sheet - Total Assets,"5,164,000.00","4,634,000.00","4,539,000.00","4,576,000.00","5,608,000.00","6,363,000.00","3,308,223.00","2,846,956.00","3,739,083.00","4,093,534.00","5,093,385.00","10,257,940.00","14,950,384.00","16,843,000.00","3,580,000.00","2,088,145.00","1,949,309.00","4,501,033.00","10,010,740.00","9,812,957.00","3,004,774.00","2,323,427.00","939,191.00","695,000.00","2,135,567.00","1,947,182.00", 
RNO,Rhinomed Limited ,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , ,-72.42%,-92.44%,-193.16%,-7.92%,-3.70%,-71.53%,-53.87%,-88.58%, 
RNO,Rhinomed Limited ,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , ,"3,030.00",--,--,"33,720.00",0.00,0.00,"210,854.00","432,460.00", 
RNO,Rhinomed Limited ,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , ,"-1,317,984.00","-881,025.00","-858,411.00","-1,128,712.00","-1,308,494.00","-19,559,713.00","-3,534,577.00","-5,316,992.00", 
RNO,Rhinomed Limited ,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , ,"1,819,953.00","953,041.00","444,395.00","15,245,076.00","20,401,549.00","5,675,695.00","6,561,625.00","5,967,479.00", 
RNO,Rhinomed Limited ,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , ,"1,985,456.00","1,051,813.00","493,825.00","15,718,809.00","25,872,261.00","6,437,566.00","7,066,130.00","6,816,606.00", 
SCU,Stemcell United Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-0.07%,-5.65%,-0.86%,2.22%,-6.15%,12.98%,1.70%,-54.51%,-11.28%, , , , , , ,0.00%,-754.94%, 
SCU,Stemcell United Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,"819,020.00","12,718,000.00","9,619,298.00","127,186,640.00","312,823,364.00","477,769,000.00","769,138,000.00","1,013,432,000.00", , , , , , ,--,0.00, 
SCU,Stemcell United Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-4,092.00","-293,306.00","-97,000.00","256,077.00","1,083,427.00","2,329,531.00","2,649,000.00","-9,967,000.00","402,000.00", , , , , , ,0.00,"75,041,240.00", 
SCU,Stemcell United Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"5,626,879.00","5,191,691.00","11,290,000.00","11,552,633.00","12,636,060.00","17,947,961.00","61,151,000.00","67,481,000.00","67,970,000.00", , , , , , ,"-76,251,378.00","149,845.00", 
SCU,Stemcell United Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"12,040,314.00","13,106,887.00","17,661,000.00","17,638,946.00","37,812,089.00","80,483,026.00","138,008,000.00","205,926,000.00","280,755,000.00", , , , , , ,"21,105.00","3,580,672.00", 
SHC,"Sunshine Heart, Inc",Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,--,-9.74%,-52.26%,-119.09%,-142.05%,-98.02%,-398.21%,-138.20%,-704.79%,-108.62%, , , , 
SHC,"Sunshine Heart, Inc",Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,--,"33,515.00","373,028.00",0.00,0.00,--,"134,195.00","298,799.00",--,--, , , , 
SHC,"Sunshine Heart, Inc",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-3,026,495.00","-1,449,422.00","-5,005,573.00","-7,035,448.00","-11,539,413.00","-9,738,183.00","-8,079,055.00","-6,532,720.00","-15,947,223.00","-13,544,876.00", , , , 
SHC,"Sunshine Heart, Inc",Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,--,"14,885,029.00","9,578,046.00","5,907,736.00","8,123,748.00","9,934,902.00","2,028,850.00","4,727,143.00","4,525,403.00","12,470,146.00", , , , 
SHC,"Sunshine Heart, Inc",Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,--,"15,024,661.00","10,020,517.00","6,401,692.00","8,381,507.00","10,178,454.00","2,457,020.00","5,265,496.00","7,316,857.00","14,479,969.00", , , , 
SIE,SciGen Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,0.00%,-13.52%,-13.57%,-5.43%,3.12%,-22.69%,-125.05%,129.18%,22.83%,9.20%,-0.19%,-0.68%,-4.38%,-2.21%, 
SIE,SciGen Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,--,"2,269,787.00","5,215,921.00","5,288,125.00","3,900,107.00","9,438,520.00","20,005,773.00","12,544,319.00","12,170,618.00","15,520,874.00","17,478,813.00","23,234,242.00","28,779,565.00","32,202,299.00", 
SIE,SciGen Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,0.00,"-4,154,042.00","-3,643,201.00","-4,325,375.00","217,588.00","-4,608,666.00","-12,245,958.00","-45,001,672.00","-10,034,438.00","-17,454,706.00","3,989,791.00","-790,120.00","-2,075,103.00","1,735,559.00", 
SIE,SciGen Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,"41,465,906.00","30,714,893.00","26,856,249.00","79,604,945.00","27,311,464.00","23,341,651.00","17,735,277.00","-28,641,989.00","-38,180,655.00","-55,869,436.00","-51,196,070.00","-61,936,745.00","-71,420,385.00","-78,547,768.00", 
SIE,SciGen Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,"47,292,504.00","35,926,808.00","29,464,210.00","62,040,594.00","62,798,977.00","85,021,551.00","138,109,122.00","79,410,190.00","64,507,527.00","57,227,254.00","50,630,778.00","52,206,079.00","39,207,510.00","43,547,768.00", 
SLA,Solagran Limited,Annual Ratio Analysis - ROE,-103.15%,-257.14%,-850.00%,-15.77%,-143.08%,-190.14%,-60.75%,-602.10%,162.17%,-492.47%,-35.48%,-229.27%,895.91%,-7.38%,-14.24%,-21.34%,-21.12%,-33.38%,-17.08%,-57.45%,-20.44%,-47.42%,"2,616.46%",118.85%,44.86%,38.47%, 
SLA,Solagran Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,"14,000.00",0.00,0.00,0.00,0.00,0.00,0.00,--,"978,841.00",0.00,0.00,0.00,0.00,"64,977.00",0.00,"124,541.00","335,187.00","575,678.00","1,221,103.00","1,019,383.00","1,813,155.00","1,610,255.00","2,085,725.00","2,533,081.00", 
SLA,Solagran Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,729,000.00","-113,000.00","-102,000.00","-347,000.00","-3,318,000.00","-1,430,000.00","-1,817,643.00","-627,786.00","-570,452.00","-246,672.00","-3,957,353.00","-11,424,961.00","-2,101,911.00","-165,265.00","-1,312,316.00","-2,115,204.00","-2,113,001.00","-3,649,964.00","-3,762,040.00","-10,375,504.00","-4,548,007.00","-9,103,863.00","-18,439,749.00","-4,892,800.00","-3,930,046.00","-6,441,971.00", 
SLA,Solagran Limited,Annual Balance Sheet - Total Equity,"127,000.00","14,000.00","12,000.00","1,268,000.00","130,000.00","142,000.00","465,873.00","38,087.00","-351,765.00","102,504.00","10,026,254.00","1,979,286.00","-122,625.00","9,119,628.00","9,217,482.00","9,914,135.00","10,006,214.00","10,936,052.00","21,732,362.00","17,578,474.00","20,861,065.00","18,546,028.00","-366,892.00","-4,116,942.00","-8,760,106.00","-16,746,833.00", 
SLA,Solagran Limited,Annual Balance Sheet - Total Assets,"267,000.00","101,000.00","146,000.00","1,456,000.00","495,000.00","550,000.00","796,134.00","414,217.00","412,108.00","413,841.00","12,023,437.00","3,220,395.00","422,663.00","9,818,619.00","9,378,323.00","10,068,728.00","10,326,260.00","12,688,773.00","26,898,513.00","19,411,255.00","23,337,652.00","28,046,335.00","13,973,114.00","14,475,379.00","13,577,623.00","6,833,004.00", 
SPL,Starpharma Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,--,-6.14%,-15.68%,-46.48%,-83.52%,-31.25%,-76.12%,-35.29%,-28.16%,-36.75%,-16.18%,-18.30%,-32.25%,-28.07%,-11.38%,-44.41%,-50.46%, 
SPL,Starpharma Holdings Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,0.00,0.00,0.00,0.00,"384,703.00","911,335.00","15,730.00","13,922.00",500.00,"863,854.00","1,412,000.00","2,019,000.00","1,404,000.00","1,144,000.00","44,000.00","20,000.00","273,000.00","804,000.00", 
SPL,Starpharma Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-1,270,797.00","-1,169,167.00","-1,772,014.00","-3,906,427.00","-7,959,289.00","-7,544,721.00","-5,497,850.00","-7,585,992.00","-7,522,789.00","-7,244,996.00","-7,491,000.00","-4,127,000.00","-6,378,000.00","-8,930,000.00","-13,658,000.00","-5,229,000.00","-14,635,000.00","-18,950,000.00", 
SPL,Starpharma Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,--,"28,853,274.00","24,915,653.00","17,266,327.00","9,243,130.00","17,592,496.00","9,965,965.00","21,315,986.00","25,724,030.00","20,383,000.00","25,499,000.00","34,844,000.00","27,693,000.00","48,651,000.00","45,968,000.00","32,951,000.00","37,558,000.00", 
SPL,Starpharma Holdings Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,--,"29,052,555.00","26,025,455.00","18,859,433.00","10,715,440.00","18,490,942.00","12,499,740.00","25,013,065.00","30,423,479.00","24,653,000.00","28,847,000.00","37,567,000.00","29,807,000.00","54,268,000.00","48,550,000.00","36,862,000.00","44,383,000.00", 
SRX,Sirtex Medical Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,-7.25%,-33.49%,-12.21%,-26.73%,19.33%,3.84%,-8.59%,9.47%,7.20%,5.20%,36.97%,31.20%,19.09%,23.25%,20.73%,22.19%,27.89%, 
SRX,Sirtex Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"19,206.00","529,384.00","400,129.00","250,775.00","378,000.00","783,000.00","10,216,000.00","9,517,000.00","11,830,000.00","22,963,000.00","33,636,000.00","38,186,000.00","65,820,000.00","64,333,000.00","70,330,000.00","82,627,000.00","96,774,000.00","129,363,000.00","176,088,000.00", 
SRX,Sirtex Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-201,506.00","-533,754.00","-1,355,047.00","-1,133,000.00","-1,978,000.00","-3,416,000.00","3,150,000.00","697,000.00","-1,442,000.00","1,807,000.00","1,566,000.00","1,210,000.00","18,229,000.00","16,080,000.00","11,479,000.00","17,103,000.00","18,270,000.00","23,868,000.00","40,345,000.00", 
SRX,Sirtex Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,"18,680,348.00","3,383,554.00","16,194,000.00","12,778,000.00","16,293,000.00","18,170,000.00","16,781,000.00","19,077,000.00","21,764,000.00","23,287,000.00","39,179,000.00","51,543,000.00","60,142,000.00","73,548,000.00","88,138,000.00","107,583,000.00","144,636,000.00", 
SRX,Sirtex Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,"18,838,455.00","4,759,682.00","16,691,000.00","13,341,000.00","18,104,000.00","20,791,000.00","20,012,000.00","25,040,000.00","28,714,000.00","28,372,000.00","49,923,000.00","66,660,000.00","76,641,000.00","96,656,000.00","117,767,000.00","148,710,000.00","201,476,000.00", 
STC,Asset Realisation Company Plc,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,-88.01%, , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,"1,344,061.00", , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"-7,948,776.00", , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"15,392,059.00","9,032,184.00", , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"18,501,240.00","11,058,476.00", , , , , , , , , 
STI,Stirling Products Limited,Annual Ratio Analysis - ROE, , , , , , , ,-1.88%,-52.83%,-22.83%,-12.24%,-14.16%,-37.95%,-416.09%,-21.21%,-35.64%,-57.34%,-97.61%,-80.40%,-334.16%,"-1,329.65%",160.73%,--,--,--,--, 
STI,Stirling Products Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,--,--,--,0.00,--,0.00,0.00,0.00,0.00,0.00,"1,840.00","398,952.00","157,988.00","84,434.00","961,133.00",--,--,--,--, 
STI,Stirling Products Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-399,026.00","-1,489,325.00","-1,427,114.00","-636,330.00","-1,158,682.00","-7,804,902.00","-4,305,787.00","-3,134,026.00","-4,889,008.00","-5,807,400.00","-5,587,249.00","-3,810,132.00","-5,084,168.00","-7,868,484.00","-13,650,123.00","7,607,624.00",0.00,0.00,0.00, 
STI,Stirling Products Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"3,292,994.00","2,818,891.00","3,888,426.00","5,199,319.00","8,182,391.00","3,869,335.00","1,034,810.00","14,774,062.00","14,895,145.00","10,108,442.00","5,723,906.00","4,739,173.00","1,521,494.00","591,772.00","-7,607,624.00",0.00,0.00,0.00,0.00, 
STI,Stirling Products Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"3,633,152.00","3,504,807.00","4,026,542.00","5,847,078.00","8,709,953.00","4,021,768.00","1,123,301.00","15,342,863.00","15,164,404.00","10,320,933.00","6,164,317.00","6,644,099.00","4,237,983.00","7,314,295.00","6,814,648.00",--,--,--,--, 
SUD,Suda Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-1.30%,-25.06%,-28.27%,-7.29%,-16.45%,0.20%,-14.01%,-93.57%,-32.91%,-44.25%,-26.39%,-23.67%,-24.93%,-14.71%,-19.50%, 
SUD,Suda Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,0.00,--,"140,768.00","4,745,548.00","8,172,827.00","8,614,000.00","9,508,161.00","11,856,260.00","19,353.00","14,215.00","3,003,798.00","3,908,869.00","4,045,060.00","8,648,187.00","5,624,815.00", 
SUD,Suda Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-79,187.00","-751,340.00","-1,064,905.00","-967,848.00","-1,928,929.00","26,079.00","-2,007,363.00","-9,647,554.00","-3,168,182.00","-4,856,312.00","-4,423,195.00","-4,437,023.00","-1,667,519.00","-2,060,850.00","-3,378,331.00", 
SUD,Suda Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"6,113,488.00","2,997,918.00","3,767,226.00","13,274,895.00","11,724,581.00","13,351,404.00","14,327,171.00","10,509,687.00","8,842,200.00","8,345,615.00","11,032,235.00","7,012,033.00","6,690,080.00","15,991,556.00","19,300,587.00", 
SUD,Suda Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"6,117,077.00","3,144,163.00","4,652,561.00","16,095,569.00","14,951,358.00","16,629,261.00","20,998,253.00","16,063,952.00","16,610,963.00","11,902,445.00","13,525,959.00","9,754,576.00","10,728,946.00","20,347,024.00","22,820,743.00", 
TDL,TBG Diagnostics Limited,Annual Ratio Analysis - ROE, , , , , , ,-44.16%,-72.80%,-196.56%,-58.79%,-40.25%,-4.56%,-33.27%,-51.79%,-32.55%,-23.29%,-42.46%,-22.92%,-34.74%,-17.76%,-105.47%,-67.82%,-60.65%,-21.52%,-22.55%,-135.31%, 
TDL,TBG Diagnostics Limited,Annual Profit and Loss - Operating Revenue, , , , , , ,"994,341.00","1,382,377.00","1,486,025.00","1,420,784.00","2,441,219.00","2,434,000.00","3,850,000.00","5,544,000.00","3,490,000.00","2,286,000.00","905,000.00","920,000.00","1,086,000.00","1,724,000.00","1,973,000.00","2,585,000.00","2,008,145.00","2,816,281.00","5,410,951.00","3,341,107.00", 
TDL,TBG Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"-2,912,474.00","-3,363,733.00","-5,387,233.00","-7,372,331.00","-7,322,244.00","-1,147,000.00","-6,156,000.00","-7,578,000.00","-4,781,000.00","-5,937,000.00","-7,609,000.00","-22,454,000.00","-26,148,000.00","-5,467,000.00","-15,839,000.00","-6,098,000.00","-3,440,398.00","-2,092,134.00","-1,806,945.00","-4,684,104.00", 
TDL,TBG Diagnostics Limited,Annual Balance Sheet - Total Equity, , , , , , ,"6,595,661.00","4,620,435.00","2,740,747.00","12,539,352.00","15,857,107.00","25,160,000.00","18,501,000.00","14,631,000.00","16,780,000.00","25,491,000.00","17,920,000.00","97,977,000.00","75,259,000.00","30,790,000.00","15,017,000.00","8,991,000.00","5,673,002.00","9,722,511.00","8,013,922.00","3,461,752.00", 
TDL,TBG Diagnostics Limited,Annual Balance Sheet - Total Assets, , , , , , ,"7,098,909.00","5,420,333.00","4,179,626.00","13,831,292.00","17,485,906.00","26,758,000.00","20,882,000.00","17,218,000.00","18,625,000.00","27,018,000.00","19,793,000.00","100,640,000.00","82,591,000.00","32,662,000.00","17,184,000.00","12,180,000.00","7,375,972.00","10,554,638.00","9,668,220.00","5,056,665.00", 
TDX,Tyrian Diagnostics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,--,--,--, ,-151.49%,-140.95%,-263.24%,-115.52%,-218.67%,-123.81%,-158.04%,-203.48%,-16.87%,9.22%,-54.73%, 
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"3,969,000.00","5,391,000.00",--, ,"3,584,619.00","4,558,056.00","3,353,010.00","1,551,474.00","790,573.00","1,516,776.00","467,606.00","101,752.00",0.00,"460,961.00","22,383.00", 
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-7,473,000.00","-16,248,000.00","-16,397,000.00", ,"-19,766,147.00","-10,214,981.00","-8,772,571.00","-8,726,511.00","-6,995,002.00","-4,155,911.00","-4,383,868.00","-1,865,210.00","-132,360.00","79,709.00","-305,624.00", 
TDX,Tyrian Diagnostics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,--,--,--, ,"6,407,276.00","7,247,443.00","3,332,532.00","7,553,986.00","2,934,323.00","3,336,273.00","2,762,219.00","916,734.00","784,374.00","864,083.00","558,459.00", 
TDX,Tyrian Diagnostics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,--,--,--, ,"11,097,637.00","10,092,655.00","5,275,196.00","9,767,037.00","4,583,307.00","4,489,765.00","4,102,765.00","1,267,722.00","976,871.00","898,205.00","596,089.00", 
TEO,Telesso Technologies Limited,Annual Ratio Analysis - ROE, , , , , , , ,-14.56%,0.21%,"12,348.00%",-147.64%,-174.22%,-104.73%,-68.43%,-187.09%,-172.92%,-64.65%,-18.98%,-20.98%,-49.48%,-43.62%,-30.74%,-30.71%,-407.82%, , , 
TEO,Telesso Technologies Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"6,150,000.00","20,064,000.00","17,417,000.00","13,017,000.00","9,187,746.00","144,845.00","36,134.00","34,621.00","383,159.00","773,629.00","320,399.00","423,484.00","441,376.00",--,--,0.00,0.00, , , 
TEO,Telesso Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-1,091,000.00","-5,000.00","-5,812,000.00","-1,235,000.00","-3,661,343.00","-2,472,312.00","-4,877,935.00","-3,836,893.00","-3,518,847.00","-783,391.00","-1,214,156.00","-1,124,703.00","-1,777,323.00","-1,082,212.00","-583,349.00","-445,935.00","-1,191,974.00", , , 
TEO,Telesso Technologies Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"5,354,000.00","5,824,000.00","-25,000.00","2,206,000.00","1,349,647.00","991,110.00","5,575,156.00","2,057,900.00","1,679,095.00","1,211,683.00","6,397,551.00","5,361,721.00","3,591,920.00","2,481,149.00","1,897,800.00","1,451,865.00","292,280.00", , , 
TEO,Telesso Technologies Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"13,060,000.00","15,510,000.00","10,702,000.00","13,599,000.00","5,219,334.00","4,544,006.00","7,219,546.00","3,028,047.00","2,132,191.00","1,516,260.00","7,607,146.00","5,587,820.00","3,935,604.00","2,582,512.00","2,069,811.00","1,551,094.00","596,991.00", , , 
TPE,TPI Enterprises Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
TPE,TPI Enterprises Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
TPE,TPI Enterprises Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
TPE,TPI Enterprises Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"20,627,613.00", 
TPE,TPI Enterprises Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"41,529,542.00", 
VBS,Vectus Biosystems Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
VBS,Vectus Biosystems Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
VBS,Vectus Biosystems Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
VBS,Vectus Biosystems Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"11,218,005.00", 
VBS,Vectus Biosystems Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"11,728,577.00", 
VLA,Viralytics Limited,Annual Ratio Analysis - ROE,-17.28%,-131.91%,-566.43%,101.39%,36.96%,139.86%,44.40%,-33.20%,-133.92%,-180.90%,-415.02%,-563.09%,-178.29%,-64.78%,1.71%,-67.76%,-97.26%,-35.87%,-42.34%,-93.73%,-55.77%,-29.82%,-49.99%,-46.00%,-19.15%,-17.11%, 
VLA,Viralytics Limited,Annual Profit and Loss - Operating Revenue,"200,000.00","181,000.00","213,000.00","509,000.00","631,000.00","623,000.00","823,190.00","892,077.00","1,012,169.00","911,758.00","1,073,447.00","1,069,122.00","1,003,911.00","1,047,792.00","953,258.00","419,233.00","7,533.00","359,473.00",0.00,--,0.00,"1,405,503.00","871,603.00",0.00,0.00,0.00, 
VLA,Viralytics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-491,000.00","-1,050,000.00","-653,000.00","-7,355,000.00","7,258,000.00","106,000.00","214,226.00","-434,025.00","-762,862.00","-1,251,679.00","-887,629.00","-3,455,250.00","-1,425,760.00","-2,436,978.00","-3,129,315.00","-6,940,616.00","-9,272,383.00","-4,195,590.00","-3,681,125.00","-4,585,443.00","-4,804,370.00","-2,701,287.00","-4,778,819.00","-4,129,729.00","-5,528,629.00","-4,254,777.00", 
VLA,Viralytics Limited,Annual Balance Sheet - Total Equity,"1,835,000.00","796,000.00","143,000.00","-7,212,000.00","46,000.00","429,000.00","1,161,912.00","1,303,087.00","550,225.00","601,506.00","213,877.00","613,627.00","1,782,938.00","3,046,131.00","8,159,907.00","8,703,198.00","9,533,294.00","11,695,864.00","8,694,450.00","4,892,184.00","8,614,325.00","9,058,460.00","9,559,874.00","8,977,885.00","28,876,542.00","24,872,281.00", 
VLA,Viralytics Limited,Annual Balance Sheet - Total Assets,"3,616,000.00","2,461,000.00","403,000.00","282,000.00","261,000.00","5,218,000.00","5,546,263.00","7,115,395.00","6,499,956.00","6,304,207.00","3,460,452.00","3,486,214.00","35,454,713.00","3,743,182.00","8,965,918.00","9,136,356.00","12,382,731.00","12,251,852.00","9,176,045.00","6,540,160.00","9,539,534.00","10,039,649.00","10,305,957.00","10,212,771.00","29,643,327.00","26,557,545.00", 
VSC,Vita Life Sciences Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-50.64%,-21.36%,-9.62%,58.28%,14.28%,21.03%,29.35%,33.91%,19.24%, 
VSC,Vita Life Sciences Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,"11,869,884.00","14,356,081.00","17,015,128.00","20,190,561.00","24,266,646.00","30,191,000.00","35,411,000.00","36,580,000.00","38,584,000.00", 
VSC,Vita Life Sciences Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-204,265.00","353,477.00","-328,193.00","4,459,519.00","1,212,521.00","2,316,000.00","4,746,000.00","7,284,000.00","4,351,000.00", 
VSC,Vita Life Sciences Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"2,879,728.00","3,845,624.00","3,900,881.00","8,129,883.00","8,956,045.00","11,342,000.00","16,269,000.00","21,565,000.00","22,876,000.00", 
VSC,Vita Life Sciences Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"6,729,107.00","8,640,588.00","8,810,066.00","14,512,224.00","13,349,160.00","16,813,000.00","22,009,000.00","30,271,000.00","32,388,000.00", 
ZTL,Zenyth Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , ,-3.99%,-12.97%,-15.15%,-25.47%,-21.18%,-23.23%,1.70%,-2.69%,2.09%,-8.97%, , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"112,181,000.00","124,363,000.00","117,675,000.00","109,238,000.00","43,606,000.00","3,166,000.00","1,015,000.00","598,000.00","764,000.00","431,000.00", , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-2,498,000.00","-6,454,000.00","-10,767,000.00","-20,223,000.00","-4,337,000.00","-14,402,000.00","7,388,000.00","-3,523,000.00","-1,622,000.00","-4,429,000.00", , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"110,243,000.00","108,261,000.00","94,747,000.00","71,445,000.00","61,354,000.00","61,988,000.00","69,376,000.00","64,167,000.00","53,653,000.00","49,369,000.00", , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"135,067,000.00","162,905,000.00","153,542,000.00","117,282,000.00","88,890,000.00","86,048,000.00","78,575,000.00","67,362,000.00","56,636,000.00","52,648,000.00", , , , , , , , , , 
